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Abstract
Modeling the Transport and Inhibition Kinetics of the Human Multidrug Resistance
Transporter P-Glycoprotein in MDCK-II Cells
Poulomi Acharya
Advisor: Dr. Joe Bentz
The human multidrug resistance transporter P-glycoprotein (P-gp) eﬄuxes a wide
range of substrates and can be affected by a wide range of inhibitors or modulators.
Many studies have presented classifications for these binding interactions, within either
the context of equilibrium binding or the Michaelis-Menten enzyme analysis of the AT-
Pase activity of P-gp. Our approach is to study P-gp transport and its inhibition using a
physiologically relevant confluent monolayer of hMDR1-MDCKII cells. We measure the
elementary rate constants for P-gp eﬄux of radiolabeled substrates and study inhibition
using pair wise combinations with a different unlabeled substrate acting as the inhibitor.
Our current kinetic model for P-gp has only a single kinetically relevant eﬄux-connected
binding site. We conclude that there are at least two kinetically distinct eﬄux pathways
through P-gp and the binding sites connected to these pathways may not be exclusive for
any drug. Binding of these substrates must be cooperative which can be either positive
or negative based on the substrate-inhibitor pair. From the transport and inhibition of
digoxin and loperamide, we found that other transporters are responsible for uptake of
these drugs into the cells and for recycling them into and from the apical membrane once
P-gp has pumped them out. Each drug has a particular IC-50 for inhibiting transport of
another. Exhaustive computer simulations of drug transport in the presence of “virtual
inhibitors” showed that the fitted IC50 values overestimate the intrinsic dissociation con-
stant, KI,Aq and an equation showed that this overestimate is contributed by a convolution
of cell and substrate parameters. The smaller the passive permeability of the substrate,
xii
the greater is the magnitude of the overestimate of the inhibitor’s dissociation constant by
its IC50. These conclusions are valid for any membrane transporter whose substrates and
inhibitors must pass a permeability barrier to reach their binding site on the transporter.
Part I - Introduction
11. Diseases and Multidrug resistance
1.1 Membrane transporters and the ABC family
Various solutes, nutrients, and ions move across cell membranes with the help of trans-
porters, which constitute 15% to 30% of membrane proteins in a cell. Transport processes
consume 60% of the energy in mammalian cells (Sauna and Ambudkar, 2007). Higgins et
al. (1985) defined the ATP-binding cassette (ABC) superfamily of proteins. It represents
one of the largest and most diverse groups of transport proteins (Dean et al., 2001). Ap-
proximately 1,100 different transporters belonging to this family have been described in the
literature (Dean and Annilo, 2005). There are 80 ABC transporters in E.coli making up 2%
of its genome (Dean et al., 2001). The importance of these proteins in membrane transport
is indicated by the large number of ABC genes, their ubiquitous occurrence, and primordial
origin (Gottesman and Ambudkar, 2001). Luckie et al. (2003) have compiled a list of hu-
man ABC genes, their chromosomal location, and function. Dr. Michael Dean at the Na-
tional Cancer Institute has an exhaustive portal for genetic information on ABC genes and
the proteins encoded by them (http://theta.ncifcrf.gov/abc_central/index.php).
1.2 ABC transporters: bacteria to humans
Most ABC proteins are integral membrane transporters, either importing or exporting
their substrates, driven by the energy of ATP hydrolysis (Dean et al., 2005; Gottesman
and Ambudkar, 2001). ABC exporters extrude diverse substrates, including drugs and
xenobiotics, whereas ABC importers mediate the uptake of essential nutrients. The basic
ABC transporter architecture consists of two transmembrane domains (TMDs) that pro-
vide a translocation pathway through the membrane, and two cytoplasmic, water-exposed
2nucleotide-binding domains (NBDs) that hydrolyse ATP.
Some of the best-studied ABC exporters are the LmrA protein from Lactococcus lactis,
Pdr5 in Saccharomyces cerevisiae and P-glycoprotein (P-gp) in humans. Bacterial ABC
proteins are generally expressed as ‘half-transporters’ (e.g. LmrA) that contain one TMD
fused to an NBD, which dimerize to form the full transporter (e.g. P-gp) in higher eche-
lons of the animal kingdom (Holland and Blight, 1999). Functionally important residues
are highly conserved among the NBDs, suggesting that ABC transporters share a com-
mon mechanism of coupling ATP hydrolysis to substrate transport (Holland and Blight,
1999). It has been shown that LmrA can substitute for the human ABC transporter,
P-glycoprotein, in human lung fibroblast cells, suggesting that this type of eﬄux pump is
conserved from bacteria to man (Van Veen et al., 1998; Zgurskaya et al., 2002).
1.3 Role of ABC transporters in diseases
Out of the 50 human ABC proteins, 17 are implicated in human diseases (Gottes-
man and Ambudkar, 2001). In humans, mutations in ABC transporter genes cause many
genetic disorders which affect various organs directly or indirectly. These include but
are not limited to Tangier disease (caused by mutations in ABCA1 also called cholesterol
eﬄux regulatory protein or CERP), Stargardt disease (affects the eye caused due to muta-
tions in ABCA4), Wegener’s granulomatosis (immune system), Dubin-Johnson syndrome
(liver, ABCC2), adrenoleukodystrophy (ABCD1), Pseudoxanthoma elasticum (ABCC6).
Defects in CFTR (Cystic Fibrosis Transmembrane Regulator or ABCC7) cause Cystic Fi-
brosis. ABC proteins are involved in conferring multidrug resistance to several cytotoxins
(antibiotics, antifungals, herbicides and anti-neoplastics) in cells: starting from bacteria
(Poelarends et al., 2002) to humans (Higgins and Linton, 2004). In microorganisms, they
confer resistance to antibiotics and other bacteriostatic compounds via export pumps like
LmrA and Pdr5 (Van Veen et al., 2001).
31.4 Multidrug resistance
Multidrug resistance (MDR) is the phenomenon by which cells develop resistance to a
wide variety of structurally and functionally unrelated compounds. Multidrug resistance
is an alarming and rapidly growing obstacle in the treatment of infectious diseases, cystic
fibrosis, human immuno-deficiency virus (HIV), malaria, and cancer. Drug-resistant bac-
terial strains that cause gonorrhea, pneumonia, cholera, and tuberculosis are widespread
and difficult to treat (Ouellette et al., 2001). It has been estimated that 40% of all human
cancers develop multidrug resistance, making it a major obstacle to the effective treat-
ment of cancer (Sauna and Ambudkar, 2007). In humans, ABC transporters implicated in
MDR are the breast cancer resistance protein (ABCG2), P-glcoprotein (P-gp or ABCB1)
and multidrug resistance protein 1 (ABCC1).
1.5 P-gp and MDR
P-gp was first recognized as a major potential hindrance to successful chemother-
apy because of its over-expression in malignant cells and was later realized to function
physiologically in polarized epithelia. It is involved in the absorption, distribution and
elimination of diverse classes of hydrophobic xenobiotics, drug molecules, environmental
and dietary toxins (Senior et al., 1995; Lown et al., 1997; Schinkel, 1998; Goh et al., 2002;
Gottesman et al., 2002). P-gp can mediate clinically relevant drug-drug interactions which
can even lead to fatal systemic toxicity. The mechanism in which these interactions occur
is of great interest. The general potential of MDR transporters in reducing the efficacy of
many hydrophobic drugs, new and old, have made P-gp a target of intense investigation.
It is a challenge for researchers to get an insight into the mechanism of action of this
transporter. This is central to the development of newer therapeutic approaches in the
treatment of several human diseases.
42. Going back in time: Literature review of work done on P-gp
Here I will attempt to trace the sequence of milestones in P-gp related research.
2.1 MDR: cellular physiology and biochemistry
In this section I will summarize the early work done trying to understand the under-
lying cause for the observed genetic, physiological and biochemical changes in MDR cells.
In this respect it becomes important to define the MDR phenotype. Cells selected for
resistance with one drug display significant cross-resistance to other drugs. This fairly
consistent pattern of cross-resistance is termed the MDR phenotype. It is a dominant
trait in which cells show increased eﬄux and hence less accumulation of xenobiotics and
MDR reversing agents can inhibit this eﬄux.
2.1.1 MDR is associated with alterations in the karyotype
Kessel et al. (1968) isolated multidrug resistant Chinese Hamster Ovary (CHO) cells
followed by the demonstration of cytogenetic abnormalities like random chromosomal re-
arrangements and DNA duplication in MDR cells. These results were consistent with gene
amplification (Beidler and Riehm, 1970).
2.1.2 Characteristic features of MDR
Increased drug eﬄux, reduced drug accumulation and cross resistance to many com-
pounds are constitutive features of MDR. Dano (1973) showed that there is increased
daunomycin eﬄux (resulting in decreased accumulation) in MDR cell lines (Ehrlich as-
cites tumor cells) in presence of ATP. MDR cells depleted of ATP resulted in less eﬄux
and more accumulation, Daunomycin eﬄux was inhibited by metabolic inhibitors and
5structural analogs (N-acetyl daunomycin). These observations along with the fact that
the accumulated steady-state level of daunomycin increased in the presence of Vinca al-
kaloids, to which the tumor cells were cross-resistant, led him to conclude that an energy-
dependent carrier-mediated extrusion mechanism is involved and that the Vinca alkaloids
competed with daunomycin. Ling et al. (1974) showed colchicine resistance is correlated
to resistance to other drugs and reduced drug uptake. In the same year, they isolated CHO
cells showing reversion of MDR phenotype. Subsequently, See et al. (1974) found that
colchicine accumulation in cell lines derived from colchicine resistant CHO cells denoted
the CHR was energy dependent.
2.1.3 Finding underlying reason for MDR
Ling and Thompson (1974) studied initial rates of colchicine uptake under different
conditions. Ling (1975) suggested that a global effect on the cell membrane (contributed
by an active permeability barrier) must be the cause for the MDR phenotype. They
proposed that a “modulator” of membrane lipid fluidity could be the basis for this, perhaps
involving phosphorylation /dephosphorylation of membrane proteins. In the same paper,
independent revertant clones selected in a single step from the two highly resistant lines
(CHR C5 and CHR C4) showed that the MDR and the CHR phenotype both co-reverted.
This meant that the MDR phenotype is caused by alteration in a single gene. Note that
the gene encoding P-gp was isolated a few years later as described in the following section.
Juliano and Ling (1976) found that P-gp is expressed in CHR cell lines but not in
wild type cells. Riordan and Ling (1979) purified a 170000 Dalton protein as a prominent
Coomassie blue stained band from CHR cells. They named the protein in the band P-
glycoprotein (P-gp) because of its association with colchicine permeability. They showed
that P-gp is localized in the plasma membrane in significant amounts (estimated to be
3-4% of total plasma membrane protein) in a highly colchicine-resistant line. The results
6of this study led to the possibility that isolated plasma membrane vesicles could be used
for in vitro drug uptake studies and that P-gp could be purified (once the gene was isolated
and cloned) for reconstitution studies and used to raise antisera.
These and other observations about the cellular pharmacology in MDR cells led to
an acceptance of the hypothesis that P-gp, an outward transport pump of broad speci-
ficity might be responsible for increased drug eﬄux in MDR cells that results in altered
sensitivity to multiple drugs.
2.2 MDR: Molecular biology and mechanism
In the following section I will collate the findings that attempt to show that P-gp was
the protein responsible for the MDR phenotype.
2.2.1 MDR is a dominant trait
Ling and Baker (1978) showed that MDR is a dominant phenotype using hybrid CHO
cells in which colchicine resistance was dominant. Debenham et al. (1982) showed that
genomic DNA from CHR cells transfected into drug-sensitive mouse cells resulted in the
expression of MDR phenotype. Since such a system retains very little donor DNA in the
recipient cell and non-linked genes are not normally co-transferred, they concluded that
both the CHR and MDR phenotypes are the result of a mutation in a single gene or a
small number of linked genes. This confirmed that MDR is a dominant phenotype.
2.2.2 Cloning of the MDR1 gene
Roninson et al. (1984) cloned gene fragments in CHR cell lines selected with different
drugs. Kartner et al. (1985) isolated monoclonal antibodies to P-gp. Riordan et al. (1985)
used these antibodies to show that P-gp is encoded by a multigene family clustered in one
amplicon in MDR mammalian cell lines. Van der bliek et al. (1986) showed that there
7are 5 genes clustered in this amplicon and P-gp is encoded by one of them. Gros et al.
(1986a) cloned the first mdr coding sequence and demonstrated a 5 kb mdr mRNA message
in multidrug-resistant hamster cell lines. In the same year, the full-length MDR1 gene
was cloned and its homology to bacterial ATP-dependent transporters was demonstrated
(Gros et al., 1986b). Roninson et al. (1986) found MDR1 and MDR2 genes in a human
nasopharyngeal carcinoma cell line. Ueda et al. (1986) showed that the MDR1 gene
encodes P-gp.
2.2.3 Characterization of function
Functional assays in-vitro:
Gerlach et al. (1986) proposed that P-gp is an export pump based on similarities
between 3’ half of P-gp cDNA and Hemolysin B. Ueda et al. (1987a) created a full-length
clone in a retroviral expression system and showed that individual transfectant cell lines
were fully multidrug-resistant. This was the first evidence that P-gp by itself can confer
properties related to MDR. Cornwell et al. (1986a) showed that membranes containing P-
gp bound to vinblastine and they also performed photo affinity labeling of P-gp (Cornwell
et al., 1986b). Horio et al. (1988) showed that P-gp in membrane vesicles transported
drugs.
It was shown that verapamil (Tsuruo et al., 1981) and quinidine (Tsuruo et al., 1984)
could overcome vincristine resistance by increasing cytotoxicity of vincristine in P388
leukemia cells, a vincristine resistant P388 cell line and also in mice harboring these cells.
Hamada and Tsuruo (1988) purified P-gp to homogeneity by affinity chromatography
and showed that it had ATPase activity. Ambudkar et al. (1992) reconstituted purified
P-gp into vesicles and showed ATPase activity stimulated by vinblastine transport. It
was shown that P-gp could catalyze transepithelial transport in both transfected (Pastan
et al., 1988) and naturally occurring cell lines (Horio et al., 1989). This assay, using
8dog, pig, or human kidney cells, is now a standard test for transport by P-gp and other
ABC transporters in polarized epithelia. This is also used to study transport in P-gp
overexpressing cells like CACO cells derived from human colonic adenocarcinoma.
2.2.4 In vivo P-gp mediated drug resistance:
Galski et al. (1989) showed that mice expressing MDR1 gene in bone marrow are
resistant to daunomycin. Sorrentino et al. (1992) showed retroviral transfer of MDR1 in
bone marrow cells conferred in vivo drug resistance. Schinkel et al. (1994) showed MDR1
knock out mice have blood-brain barrier defects and exemplify altered pharmacokinetics
of drugs. This shows that P-gp is responsible for defending the blood- brain barrier,
controlling drug absorption and facilitating proper disposition of drugs in normal animals.
These findings are important because they are based on in vivo studies focusing on P-gp’s
native function and physiologically relevant effects of MDR. Thus, research for over 30
years has advanced from one milestone to the next finally demonstrating P-gp is an eﬄux
pump of broad specificity providing the molecular basis for MDR both in vitro and in
vivo.
2.3 Expression of P-gp
2.3.1 P-gp in normal cells
Thiebaut et al. (1989) studied the expression pattern of P-gp in normal tissues by
immunohistochemistry. P-gp is expressed in a large number of cells like the biliary canalic-
ular surface of hepatocytes, apical surface of columnar epithelial cells in intestine, brush
border membrane of proximal tubule in kidney, sub-apical surface of choroid plexus epithe-
lium, endothelial cells of blood brain barrier, microvillus border of syncytiotrophoblasts of
human placenta, several leukocyte lineages, endothelium of blood vessels of the heart, pan-
9creatic ductules and adrenal cortex (in males only). P-gp expression shows inter-individual
variations. High levels of P-gp are expressed in brain, testes, uterus, skin and eye. P-gp
is localized in both the olfactory epithelium and the endothelial cells that surround the
olfactory bulb. It is also present in alveolar type I epithelium within human and rat lung
tissue (Srinivas et al., 2006).
2.3.2 P-gp in cancer cells
Goldstein et al. (1989) showed that MDR1 was expressed at levels thought to be
sufficient to confer MDR in many epithelial cancers derived from colon, liver, and kidney, in
hematopoeitic cancers (Acute myeloid leukemia or AML, Acute Lymphoblastic Leukemia,
lymphoma) and solid tumors (breast, ovary) that had relapsed after chemotherapy with
P-gp-affected agents, and also appeared occasionally in cancer simply as a result of the
transformation process. P-gp is also over expressed in lung and bone cancers. Noonan et
al. (1990) performed RT-PCR to show widespread MDR1 expression in human cancers.
2.3.3 P-gp in internal membranes
P-gp is not only expressed on cell surfaces but also in membranes of cellular organelles.
P-gp is expressed and functional on the luminal side of Golgi stack membranes and in small
amounts in the endoplasmic reticulum of several MDR cell lines (Molinari et al., 1994).
Moreover, P-gp has also been detected by immunogold labeling along the nuclear envelope
in rat microglial cells (Lee et al., 2001), and in astrocytes (Ronaldson et al., 2004).
2.3.4 Regulation of P-gp expression
Regulation of P-gp expression has been studied by several groups. Ueda et al. (1987b)
identified a 1-kilobase (kb) genomic fragment containing the major transcription initiation
sites for the human MDR1 gene. The 0.43-kb region upstream from the major transcrip-
10
tion initiation site had a consensus CAAT box and two GC box-like sequences, but no
TATA sequence. Scotto (2003) has reviewed the knowledge about the transcriptional
control of ABC transporter expression levels. Transcription of MDR1 is regulated by an
initiator or Inr element and transcription factors like NF-Y, members of the Sp family
and Kruppel family. Tumor suppressors like p53 and oncogenes (e.g. Fos and Jun fami-
lies) also control its transcription. Epigenetic induction of MDR1 expression by transient
exposure to different chemotherapeutic drugs was demonstrated (Chaudhary and Ronin-
son, 1993). However, the most convincing direct evidence to date, confirming selection
for MDR1 expression occurs in vivo in human cancers came from Mickley et al. (1997)
who have shown that rearrangements involving an upstream promoter frequently occur in
drug-resistant cancers.
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3. New directions for P-gp research
In recent times, researchers are moving onto study drug-transporter interactions and
pharmacokinetics using micro-dialysis (Bouw et al., 2001), hepatocyte cultures in collagen
gel mixture or between double layers of collagen in sandwich configuration called sandwich
cultures (Annaert et al., 2001) and organ perfusion systems (Booth et al., 1998; Mls et
al., 2005). These systems represent the invivo milieu more realistically than confluent
cell culture models. Animal models (knockouts) (Cutler et al., 2006) and whole animal
imaging techniques are also emerging since the ultimate goal is to understand the biology
of the MDR phenomenon and develop ways to counter it in humans. Sasongko et al.
(2005) have tried to image P-gp activity using C11- verapamil as the substrate at the
human blood brain barrier using positron emission tomography. This is a very powerful
tool that enables us to visualize in vivo transport and its consequences. Silicon Chips
(pioneered by Dr.Linda Griffith, MIT and Dr. Sangeeta Bhatia, UCSD) designed to grow
liver cells in an in vivo environment are being tested to study transport.
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4. P-gp: an enigma for years
4.1 Structural studies
4.1.1 Overall structure of P-gp
P-gp, the product of the human MDR1 gene is a 170kDa glycosylated integral mem-
brane protein with two identical halves. Its 1280 amino acids are organized as two ho-
mologous halves that are joined by a linker region. Each half consists of a transmem-
brane domain (TMD) comprising of 6 transmembrane helices which together form the
drug-binding site(s) and one nucleotide (ATP in this case) binding domain (NBD) which
projects into the cytosol. Thus, P-gp has discrete NBDs and drug-binding sites and the
protein is believed to perform two separate, yet coupled, functions: ATP hydrolysis and
substrate transport. The nature of interaction between the transporter and its substrates
still remains largely unknown.
TMD structure:
Each of the 12 membrane-spanning segments consist of 21 amino acids in length pre-
dicted to exist as an α-helix and are separated by six extra cellular hydrophilic loops, one of
which is glycosylated. Among the transmembrane domains, Loo and Clarke (1999) demon-
strated that TM6 and TM12 might be particularly important for drug transport because
they directly connect the two transmembrane domains to their respective ATP-binding
domains. Both transmembrane segments may interact and undergo essential conforma-
tional changes during drug binding or during ATP hydrolysis. There are intra-cytoplasmic
domains or ICDs which are believed to relay events at the NBDs to the TMDs (Loo and
Clarke, 2005b).
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NBD structure:
Although the TMDs show little sequence homology, the NBDs of all ABC proteins show
extensive amino acid sequence identity and conserved motifs. These include the Walker
A and Walker B, common to most proteins that bind nucleotide, and the signature motif
(LSGGQ motif, linker peptide, or C motif), which is diagnostic of ABC proteins (Loo et
al., 2003). The Walker A motif (Gly-X-X-Gly-X-Gly-Lys-Ser/Thr-Ser/Thr) is a glycine-
rich loop. Residues within this motif interact with the phosphate groups of the bound
nucleotide complex. The Walker B motif is (H-H-H-H-Asp), where H is a hydrophobic
residue. This sequence constitutes a buried β-strand within the core of the NBD (Smith
and Rayment, 1996). The C motif (Leu-Ser-Gly-Gly-Gln-Gln/Arg/Lys-Gln-Arg) exists
within each NBD of all the ABC proteins. This motif is located immediately next to
the N-terminal of Walker B motif and is believed to be involved in interactions with the
TMDs. The Walker A and Walker B motifs hydrogen bond extensively to the bound
ATP. Walker B also contributes the catalytic base. In addition, they contain the D-loop,
H-loop, and Q-loop and it has recently been proposed that a highly conserved A-loop (an
aromatic residue 25 amino acids upstream of the Walker A) is also an integral part of the
ABC core structure (Ambudkar et al., 2006a; Kim et al., 2006). These domains from each
NBD interact to form dimers and the characteristic ABC structural motifs are critical in
ATP binding and hydrolysis.
4.1.2 P-gp structures
Low-resolution structures of P-gp have been reported in Rosenberg et al. (1997) and
Lee et al. (2002) by electron microscopy and more recently, in Lugo and Sharom, (2005b)
based on FRET (Fluorescence Resonance Energy Transfer) studies. Rosenberg et al.
(2003, 2005) have presented a three-dimensional structure for P-gp at 8A˚ resolution ob-
tained by cryo-electron crystallography of two-dimensional crystals. These structures have
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the highest resolution for any eukaryotic ABC transporter and the first to show the organi-
zation of the transmembrane helices. Comparing nucleotide-analog-bound-P-gp with free
P-gp it was seen that upon binding of nucleotide, the transmembrane domains reorganize
into three compact structures that are each 2-3 nm in diameter and 5-6 nm in depth. This
opens a central pore along its length, potentially facilitating movement of hydrophobic
compounds from the lipid bilayer to the aqueous pore of the transporter. Fluorescence
studies (Lugo and Sharom, 2005b) have led to the belief that the drug binding site is at
the base of the central pore within the inner monolayer of the cell membrane. Since ATP-
analog binding led to significant changes in the packing of TMDs within the membrane, it
was proposed that ATP binding, rather than hydrolysis, drives the conformational changes
associated with transport.
The vanadate trapped complex of P-gp displayed a different conformation, suggesting
that rotation of TM helices takes place during the catalytic cycle. TM 4, 5, 6 in the
N-terminal half, and TM 9, 10, 11, and 12 in the C-terminal half of P-gp line the drug
binding pocket and rotation of helices 2/11 and 5/8 open and close as gates during drug
binding according to Loo and Clarke (2005a). It has been shown that TM6 and TM12
can also undergo rotation or tilting during ATP hydrolysis (Loo and Clarke, 1997; 2001a).
Moreover rearrangement of TM11 may contribute to the release of drug substrate during
ATP hydrolysis (Loo and Clarke, 2005b; Loo et al., 2005)
4.1.3 Crystal structures of other ABC proteins
Recently, two multidrug resistance proteins, AcrB (2.8A˚ resolution), a principal mul-
tidrug eﬄux transporter in Escherichia coli (Murakami et al., 2006) and sav1866 (3.0A˚
resolution) from Staphylococcus aureus were crystallized. Both of these proteins export a
wide variety of substrates.
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AcrB structure:
The cystal structures of AcrB-drug complex consists of three forms, each of which
has a different conformation corresponding to one of the three functional states of the
proposed transport cycle. Bound substrates (minocycline and doxorubicin) were in the
periplasmic domain of one of the three protomers indicated that the there is provision
for multi-site binding. They found that the binding pocket is voluminous and lined by
aromatic residues. Based on the structures it has been proposed that drugs are exported by
a three-step helix rotating mechanism in which substrates gain access to the binding site,
bind and are extruded. The shrunken drug binding pocket in the extrusion protomer led
to the suggestion that the substrates are squeezed out through a channel in the membrane.
The central α-helices seem to have an important role as a valve to open and shut the exit
from the binding pocket. Opening and closing of gates to access the drug binding site/s
by movement of transmembrane helices have been proposed for P-gp by Loo and Clarke
(2005a). Since AcrB cooperates with an outer-membrane channel, TolC, and a membrane-
fusion protein, AcrA, it is difficult to draw structural and functional homology to P-gp.
No test of functionality was performed to ensure the structure could indeed export drugs.
sav1866 structure:
Sav1866 shows significant sequence similarity to human ABC transporters of the sub-
family B that includes MDR1 (Dawson and Locher, 2006). From the sav1866 structure
a scheme for transport of substrates has been proposed. An inward-facing conformation
coincides with the substrate binding site being accessible from the cell interior, and an
outward-facing conformation with an extrusion pocket exposed to the external medium.
The structure reveals that tight interaction of the NBDs in the ATP-bound state is coupled
to the outward-facing conformation of the TMDs. In this conformation, bound substrates
may escape into the outer leaflet of the lipid bilayer or into the aqueous medium surround-
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ing the cell, depending on their hydrophobicity. Hydrolysis of ATP is expected to return
the transporter to an inward-facing conformation, again granting access to the binding
site from the cell interior. It was proposed that ABC transporters may thus use an “al-
ternating access and release” mechanism. The crystal structure is V shaped, the open
face towards the extracellular side. The in vitro ATPase activity of the protein was found
similar to that in vivo.
It should be noted that ADP, rather than ATP, was bound to the sav1866 crystal
structure although the authors claimed that the NBDs in sav1866 exhibit the conformation
of the ATP-bound state since the TMDs face outwards.
4.1.4 Canonical models for drug eﬄux by P-gp
The following models resulted from some of the early work done on P-gp and had
formed the basis for understanding the mechanistic details of P-gp mediated drug eﬄux.
Hydrophobic vacuum cleaner model:
Raviv et al. (1990) showed that daunorubicin, when photoactivated, transferred en-
ergy to INA (iodonaphthalene azide, a non-specific, hydrophobic affinity probe) which
specifically labels P-gp. Since INA is only present in hydrophobic regions of membranes,
the interaction of daunorubicin with P-gp must have been within the plasma membrane.
This resulted in the “hydrophobic vacuum cleaner” model of P-gp. In this model, drugs
are detected and extruded from the lipid bilayer into an aqueous environment; thus, P-gp
works like a phase separator that takes drugs from a hydrophobic environment and places
them in an aqueous environment. This model was supported by transport experiments
with fluorescent drugs (Bolhuis et al., 1996; Shapiro and Ling, 1997a, b, 1998; Shapiro et
al., 1997) and more recently by EPR studies employing spin-labeled verapamil (Omote and
Al-Shawi, 2002) in which ATPase activity and the movement of drugs from a hydrophobic
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to a hydrophilic environment is monitored.
Lipid flippase model:
Higgins and Gottesman (1992) proposed the flippase model which is based on the
resemblance of the drug transport process to lipid flipping. It proposes that drugs from
the inner leaflet are flipped to the outer leaflet by P-gp, where they can diffuse into the
aqueous environment around the cell, or bind to proteins such as albumin, present in
medium. This idea is supported by substantial experimental evidence with fluorescent
substrates (Sharom, 1997). The MDR3 protein, the product of the human ABCB4 gene
is primarily expressed in the bile canalicular membrane of hepatocytes and acts as a
phosphatidyl choline (PC) flippase translocating PC to the outer plasma membrane (Van
Helvoort et al., 1996). It was shown that P-gp transported several short chain analogs
of membrane lipids in transfected LLC-PK cells (Van Helvoort et al., 1996). The MDR3
protein displays 80% homology with P-gp and therefore it is possible that P-gp acts as a
broad specificity flippase.
4.1.5 Recent models for drug transport
Omote and Al-shawi (2002) have conducted kinetic experiments using spin-labeled ve-
rapamil and purified P-gp in proteoliposomes. They measure the KM , KI for the drug
and also measure activation of ATPase activity. Using EPR (Electron paramagnetic reso-
nance) spectroscopy they tried to locate the movement of SL-verapamil in the membrane
and also determined the concentration of SL-verapamil in the lipid and aqueous phases.
They found that on addition of ATP, the external aqueous concentration of SL-verapamil
was reduced and the lipid-bound component increased until steady state was achieved.
In these studies, there is no direct evidence of P-gp mediated transport but by indirectly
linking ATPase activity and movement of drug, they have tried to describe the transport
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process. Al-shawi and Omote (2005) proposed a new drug transport model of P-gp from
the results of mutagenic, quantitative thermodynamic and kinetic studies. The model ad-
vocated that drug binds first to a high-affinity loading site followed by ATP binding to the
NBD. After passing through the high-energy transition state, drug is released to the other
side of the membrane (successful transport). Different transport drugs lead to different
energy levels of the rate-limiting coupling transition state (Al-Shawi et al., 2003; Omote
et al., 2004). Omote and Al-Shawi (2006) suggest that most transported drugs can diffuse
from the surface zone of the inner leaflet of the apical plasma membrane into the initial
high affinity drug-binding site of P-gp through an open cleft. This is similar to but not
identical to the drug entry “gates” proposed by Loo and Clarke (2005a) and observed in
the two dimensional crystal of P-glycoprotein (Rosenberg et al., 2003). The mechanisms
for binding of a broad range of substrates agree with Loo and Clarke’s reported rotation
of helices 6 and 12 by ATP hydrolysis based on the cross-linking experiments (Loo and
Clarke, 2001a). Omote and Al-Shawi (2006) proposed that a “solvation” exchange mecha-
nism involving dehydration and rehydration of substrates is responsible for P-gp mediated
drug transport.
4.2 Drug binding site of P-gp
P-glycoprotein substrates generally partition into the lipid bilayer due to their hy-
drophobicity. Partitioning of drugs into the lipid bilayer is a requirement for transport
and is a major determinant of the apparent KM of the drug molecule and activation of
transport by P-gp. This was the outcome of work by various groups (Shapiro and Ling,
1995; Romsicki and Sharom, 1999; Seelig and Landwojtowicz, 2000). Several groups have
localized the drug-binding sites of P-gp to the cytoplasmic membrane leaflet (Shapiro and
Ling, 1997a, 1998; Ferry et al., 2000; Qu and Sharom, 2002; Lugo and Sharom, 2005a).
Photo-reactive drugs label the transmembrane domains 3, 4, 5, 6, 7, 8, 11 and 12 of
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P-glycoprotein (Greenberger et al., 1991; Pleban et al., 2005). In addition, mutations
in one face of TM 5, 6, 11 and 12 change substrate specificity (Loo and Clarke, 1993;
Ambudkar et al., 1999). Choi et al. (1988) also showed that point mutations change the
substrate specificity of P-gp which means individual residues are crucial for recognition
and binding. Loo and Clarke (1997, 1999, 2000, 2001a, 2003, 2005a; Loo et al., 2005) have
used Cysteine scanning mutagenesis and cross-linking agents to map the drug binding sites
of P-gp. Their studies revealed that the drug-binding site is formed by the TM regions of
both halves of P-gp, especially TM4, TM5, and TM6 in the N-terminal half, and TM9,
TM10, TM11, and TM12 in the C-terminal half (Loo and Clarke, 2005b). These studies
reveal the important amino acids involved in substrate binding since binding is altered
when these crucial residues are mutated.
Recent work suggests that the drug-binding sites of P-gp lie in a large funnel-shaped
“binding pocket” with overlapping sites formed by multiple helices from both TMDs (Loo
and Clarke, 2001b, 2005a; Loo et al., 2004; Sauna et al., 2004; Ambudkar et al., 2006b).
It is narrower at the cytoplasmic side, where TM2-TM11 and TM5-TM8 come together
(Loo and Clarke, 2005a). It may lie at the interface between the N- and C-terminal halves
of the protein (Pleban et al., 2005). In the sav1866 crystal structure described above, the
open end of the “V” faces the extra cellular side in absence of substrate or ATP. P-gp on
the other hand has the structure of an inverted “V” the open end facing the cytosol. The
nucleotide analog bound-P-gp, has a large central water filled pore through the protein
which can be compared to the “V” of the sav1866 structure. Several fluorescence based
methods have been used to measure drug binding affinity and stoichiometry. These include
covalently attached fluorophores, intrinsic Trp fluorescence, fluorescent nucleotides and
drugs. Binding affinity for several drugs have been estimated based on MIANS (2-(4’-
maleimidoanilino)-naphthalene-6-sulfonic acid) fluorescence quenching by drugs and/or
ATP (Sharom, 1997). Shapiro, Ling, and Sharom have been proponents of two functionally
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distinct drug binding sites which interact allosterically in complex ways (Shapiro et al.,
1997; Shapiro and Ling, 1997b, 1998; Lugo and Sharom 2005a, b). They are named as the
R-site, which interacts preferentially with rhodamine 123, and the H-site, which interacts
preferentially with Hoechst 33342. These sites were reported to be in the hydrophobic
membrane environment (Qu and Sharom, 2002; Lugo and Sharom, 2005a). In Lugo
and Sharom (2005a) it was reported that LDS-751 and R123 bind to different overlapping
regions, or minipockets, within the large flexible R site. It is not clear whether the putative
drug binding sites, H and R, are distinct from one another because they both have been
localized within a few angstroms of the membrane-cytosol interface.
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Oxidative cross -linking and Cys
scanning mutagenesis show 
orientation of TM helices when 
there is no ATP.
Repacking of TM helices in 
presence of ATP.TM helices 
1,11 and 6,12 tilt towards 
each other. Blue arrows show 
proposed “gates” for entry of 
drug between helices 5/8 and 
2/11. 
Figure adapted from Loo and Clarke, 2005 a,b;Loo et al.,2005.  
Figure 4.1: Figure illustrating organization of transmembrane helices involved in drug
binding
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As mentioned above, suggestions about many separate drug-binding sites with over-
lapping specificities exist but the current consensus is that there is a single, large, flexible
drug-binding pocket. Drugs are believed to interact with the amino acid residues that line
this pocket by an “induced-fit” type of mechanism, involving multiple Van der Waals and
hydrophobic interactions which can be different for each compound (Loo et al., 2003).
The transport pathway of P-gp is initiated by the binding of drug and/or ATP. It
is largely believed that the drug binds to the protein at an inward (cytoplasmic) facing
high-affinity site and is expelled via a conformational change that transforms it to a low-
affinity outward (extra cellular) facing site (Loo and Clarke, 2005b). Homology modeling,
molecular dynamics simulations and, quantitative structure activity relationship (QSAR)
studies are evolving into useful ways of understanding structure activity relationships of
P-gp (Srinivas et al., 2006).
4.3 Substrates and modulators of P-gp
4.3.1 Substrates: their structure and binding
P-gp seems to have an exceptionally broad specificity for structurally dissimilar com-
pounds (Borst & Elferink, 2002; Gottesman, 2002; Ambudkar et al., 2003). P-gp sub-
strates include but are not limited to neutral or cationic cytotoxic drugs and metabo-
lites. Examples of P-gp substrates are anthracyclines, vinca-alkaloids, epipodophyllotox-
ins, taxol, colchicine and actinomycin D, steroid hormones, cyclic and linear peptides, fluo-
rescent dyes, lipids, immunosuppressive agents, and calcium channel blockers (Holland and
Blight, 1999). A comprehensive list of P-gp substrates, inhibitors/modulators/inducers
are available at the transporters database (source: http://www.tp-search.jp/). A ma-
jority of these compounds were identified indirectly by resistance to cytotoxicity in cells
that over express P-gp. Sparreboom et al. (1997) have shown that P-gp reduces the
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oral availability of amphipathic drugs, e.g., Taxol. Likewise, most substrates are weakly
amphipathic and relatively hydrophobic; many (but not all) contain aromatic rings and
a positively charged tertiary N atom. The positive charge is often associated with 2 to
3 characteristic hydrogen bond acceptors arranged in a fixed spatial separation (Seelig,
1998; Ecker et al., 1999; Cianchetta et al. 2005).
4.3.2 P-gp Pharmacophore
A pharmacophore is the ensemble of steric and electronic features which define the
molecular framework within the active site of P-gp in 3D space based on its ability to
interact with substrates of known structures. A pharmacophore does not represent a real
molecule or a real association of functional groups, but a purely abstract concept that
accounts for the common molecular interaction capacities of a group of compounds (sub-
strates, modulators, inducers etc) with the active site. Typical pharmacophore features
are based on where a molecule is hydrophobic, aromatic, a hydrogen bond acceptor, a
hydrogen bond donor, a cation, or an anion. Pharmacophores provide conceptual tem-
plates for designing new drugs and probing the active site of a protein where these drugs
interact.
Seelig (1998) presented a basic pharmacophore model for P-gp substrates, inducers
and inhibitors using 100 compounds from literature. According to this study there are
two pharmacophore models. Type I is two electron donor groups separated by 2.5±0.3
A˚. Type II contains two electron donors separated by 4.6±0.6 A˚, possibly with a third
electron donating group between the other two. All the compounds with at least one of
these features were found to be substrates. Most of them contain at least two of these
pharmacophores, some contain as many as eight. Inducers were found to contain at least
one Type II pharmacophore but some also contain multiple Type I pharmacophores.
Wiese et al. (2001) proposed an alternate pharmacophore model for a variety of P-
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gp substrates. This study was based on a highly diverse data set and relates to the
verapamil-binding site of the protein. This model consists of two hydrophobic points,
three hydrogen bond (HB) acceptor points and one HB donor point. In a P-gp substrate
recognition study of 129 diverse compounds by 3D-QSAR, a new pharmacophoric feature
emerged. The recognition elements were two hydrophobic groups 16.5 A˚ apart and two
hydrogen bond acceptor groups 11.5 A˚ apart and the dimensions of the molecule also
played a role in substrate recognition (Cianchetta et al., 2005).
4.3.3 P-gp modulators
It has been shown that certain compounds, known as modulators (also called chemosen-
sitizers, reversers, or inhibitors), are able to reverse MDR in intact cells by blocking the
drug eﬄux activity of P-gp (Tan et al., 2000). Most modulators which are structurally
similar to transport substrates appear to bind to P-gp at the substrate-binding pocket,
and compete with them in a complex fashion. Indeed, many modulators, including ve-
rapamil and cyclosporine A, are known to be transported by P-gp. P-gp modulators
also belong to many different structural classes, and have molecular features similar to
transport substrates (Wiese and Pajeva, 2001). Drugs and modulators have been shown
to affect P-gp ATPase activity (Borgnia et al., 1996). Pascaud et al. (1998) worked on
ATPase activities of membrane vesicle suspensions and have shown that P-glycoprotein
has distinct but interacting binding sites for various modulators of its ATPase function.
Clinically, co-administration of modulators with drugs has the potential to improve up-
take in the gut and delivery to the brain as well as to increase the cytotoxicity of anti-
cancer drugs to tumor cells. Clinical trials showed survival advantage for patients with
Acute Myeloid Leukemia or AML treated with MDR inhibition plus chemotherapy (List
et al., 2001). This might help in overcoming the challenge of selectively targeting malig-
nant cells without toxic repercussions on the surrounding normal cells. Several promising
24
third-generation modulators are already being used in clinical trials (Modok et al., 2006).
4.4 ATPase reaction and eﬄux of substrates
The biochemistry of the ATPase reaction of human, mouse, and hamster P-gp have
been studied since the early 1990s, and these studies have been extensively reviewed (Al-
Shawi and Senior, 1993; Borgnia et al., 1996; Senior et al., 1998; Omote and Al-Shawi,
2002).
It has been a long drawn challenge to understand the events at the NBDs leading
to substrate eﬄux. It was shown that there is a very high basal (in the absence of any
added transport substrates) ATPase level (3-5 mmol/min/mg of protein) in purified P-gp
(Al-Shawi and Senior, 1993; Urbatsch et al., 1994). This has usually been ascribed to
the presence of an unidentified endogenous transport substrate or to lipids being flipped
in purified preparations (Borgnia et al., 1996; Romsicki and Sharom, 2001; Druley et
al., 2001). In their quest to understand the mechanism of coupling of ATP hydrolysis
to transport, Urbatsch et al. (1995) used orthovanadate to trap P-gp in the post-ATP-
hydrolysis transition state.
Following this, many groups have focused their research on the ATPase activity of P-gp
particularly trying to find out which step in the ATP binding and hydrolysis cycle provides
the “power stroke” for transport and several theories have been proposed. Ramachandra
et al. (1998) found that P-gp shows reduced affinity for photo affinity analog of drug-
substrate in the Vi trapped transition state and proposed its use to monitor conversion of
high affinity “ON” site to a low affinity “OFF” site. They proposed that ATP hydrolysis
was needed to power transport and restore ability of P-gp molecule to bind substrate.
Hrycyna et al. (1999) proposed that P-gp mediated ATP hydrolysis could be used both
for transport and to ‘reset’ P-gp conformation. Rosenberg et al. (2001) supported the
latter. It has been suggested that ATP binding rather than ATP hydrolysis provides
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the power stroke (Higgins and Linton, 2004; Al-shawi and Omote, 2005; Loo and Clarke,
2005a, b). The stoichiometry of ATP binding (and/or hydrolysis) during one catalytic
cycle has been under investigation for a long time. Senior et al. (1995), suggested that
P-gp operates by alternating-sites mechanism, in which only 1 catalytic site can be in
the transition state at any instant in time and the 2 sites alternate in catalysis. The
energy from ATP hydrolysis has been proposed to drive drug transport via relaxation of
a high-energy intermediate, with 1 ATP hydrolyzed for each drug molecule translocated
(Senior et al, 1995). Senior et al. (1998) proposed that there is cooperativity between
the ATP binding sites. It is known that P-gp binds and hydrolyses ATP molecules at
two steps during each transport cycle (Sauna and Ambudkar, 2000). Ambudkar et al.
(2006b) support that 2 molecules of ATP are hydrolyzed per cycle, the first to transport
the substrate molecule, the second to “re-set” the protein for another round of transport.
Thus the estimate ranges from 1-2 and still remains the centre of ongoing research and
intense debate.
Crystal structures of isolated NBD subunits or domains from diverse transporters
have been visualized as symmetric dimers with two molecules of ATP bound at the NBD
dimer interface (Chen et al., 2003; Hopfner et al., 2000; Smith et al., 2002; Zaitseva et al.,
2005a). FRET studies using fluorescent probes attached to the Walker A Cys residues, are
compatible with the sandwich dimer model (Qu and Sharom, 2001). Biochemical studies
of isolated NBDs have identified dimer species with 2 mol of nucleotide bound per dimer
for P-gp (Horn et al., 2003; Janas et al., 2003; Moody et al., 2002; Verdon et al., 2003;
Zaitseva et al., 2005b). However the “occluded” state contains only 1 mol ATP/mol P-gp
(Tombline et al., 2005). Sauna and Ambudkar (2007) have proposed after loose binding
of 2 ATP molecules, the sandwich dimer forms, and the tightly bound nucleotide is then
committed to hydrolysis and rapidly enters the transition state.
Ambudkar et al. (2006b) proposed a general sequence of events: ATP binding at 2
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NBDs causes the formation of NBD sandwich dimer followed by asymmetrical occlusion of
ATP from one NBD which causes conformational changes in TMDs which in turn results
in a switch from high affinity to low affinity for the substrate. Finally, the occluded
ATP is hydrolyzed and the transporter is reset to its original conformation. Higgins and
Linton (2004) have drawn analogy to several other ABC transporters and have suggested
that cooperative ATP binding and hydrolysis can enhance the kinetics for closed dimer
formation and its subsequent dissociation to the open conformation. This means that ATP
hydrolysis per se drives the thermodynamic destabilization of the nucleotide sandwich
dimer and enables the pump to “reset”. Experimental evidence is yet to be obtained to
support any one of these hypotheses.
Understanding the coupling between ATP hydrolysis and drug transport would require
high resolution structures of intact P-gp including both the NBDs and the TMDs captured
in the ground state and various intermediate steps during the catalytic cycle.
4.5 P-gp function and its membrane environment
The membrane lipid phase provides the hydrophobic environment to integral mem-
brane proteins like P-gp, and has a profound impact on their functional activity. Among
the membrane enzymes and transporters, P-gp is highly sensitive to its lipid environment
(Sharom, 1997) because of the fact that P-gp recognizes its transport substrates within the
bilayer. Romsciki and Sharom, (1998) have shown that when P-gp is reconstituted in gel
phase lipid, the Michaelis constant for ATP is lower than in liquid-crystalline lipid. Rom-
sciki and Sharom, (1999) found that binding of vinblastine, daunorubicin and verapamil
presents a 2- to 4- fold higher affinity in gel phase lipid than in liquid-crystalline lipid.
There is more transport of tetramethylrosamine, a P-gp fluorescent substrate, in the rigid
gel phase possibly due to better binding of drugs to the gel-phase, not because of changes in
P-gp function per se. In cells, lipid heterogeneity can complicate the relationship between
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P-gp function and the membrane environment (Orlowski et al., 2006).
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5. Kinetic studies
More often than not, several groups have studied the kinetics of the ATPase activity
of P-gp in presence and absence of substrates and the results of these studies have been
used to conclude about transport. Binding of drugs to P-gp and their transport have been
studied using purified and reconstituted P-gp in inside-out plasma membrane vesicles or
proteoliposomes (Shapiro and Ling, 1997a, b; Shapiro et al., 1997; Sharom and Eckford,
2003; Lugo and Sharom, 2005a, b; Loo and Clarke, 2005b). Some groups have used
cells in suspension (Ayesh et al., 1996) or unpolarized adherent cells over-expressing P-gp
(Spoelstra et al., 1994; Seelig and Gatlik-Landwojtowicz, 2005). Commonly fluorescent
(Shapiro and Ling,1997a, b, 1998; Shapiro et al., 1997; Lugo and Sharom, 2005a, b) or
radiolabelled substrates (Ayesh et al., 1996) are used to quantify binding or transport. I
will summarize the salient findings derived from studies on some of these systems.
Wang et al. (2000) measured the rate of phosphate release for ATP hydrolysis during
Hoechst transport in presence of different concentrations of other substrates in membrane
microsome preparations (derived from a drug resistant cell line) containing P-gp. Change
in fluorescence of substrates was monitored and this was correlated to their movement
between aqueous and lipid phase but this was a separate experiment and there was no
way to correlate transport to ATPase activity. They performed graphical kinetic analysis
(Lineweaver Burk, Dixon, Cornish Bowden plots) to determine KM , Vmax, KI for the
substrates tested. The aim was to determine the inhibition type and hence characterize
the modes of interaction of substrate pairs at the transport site(s). They reported that
P-gp has two unequal sites and drug binding at one site precludes, or lowers the affinity
for binding at the other site. There was no definite proof of binding to P-gp or transport
by P-gp per se. There was no way to distinguish ATPase activity due to transport of
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Hoechst from that due to transport of other substrates.
Omote and Al-shawi’s kinetic experiments using spin-labeled verapamil are explained
earlier. For many years, Sharom and associates have used purified P-gp reconstituted
in proteoliposomes and employed biochemical and fluorescent spectroscopic techniques to
measure transport into the proteoliposomes. They showed that P-gp mediated transport
is a saturable process, generating 6 to 8 fold substrate concentration gradient and is inhib-
ited by other drugs and modulators. This was quite remarkable. However, there are are
a few caveats of using this system. It is difficult to generate and measure transmembrane
drug gradients with proteoliposomes in solution. Furthermore, the hydrophobicity of the
drugs could lead to nonspecific binding with lipids within the encapsulated volume of the
proteoliposomes causing low signal to noise ratios. In Lu et al. (2001) a high affinity fluo-
rescent substrate tetramethylrosamine (TMR) was used to monitor real time transport in
proteoliposomes containing reconstituted P-gp. TMR accumulates in the aqueous phase
within the lumen of the proteoliposomes. This means that the nonspecific binding to the
lipids within the encapsulated volume, as explained before, was not an issue. The TMR
concentration gradient generated by P-gp was collapsed by the addition of the ATPase
inhibitor, vanadate, or P-gp modulators. Michaelis Menten constants for ATP binding
and hydrolysis during TMR transport were compared to those in presence and absence of
ATPase inhibitor or P-gp modulators. TMR transport was inhibited in a concentration-
dependent fashion by verapamil and cyclosporin A, and activated (probably by a positive
allosteric effect) by the transport substrate colchicine. For membrane transporters like P-
gp whose substrates reside in the inner monolayer of the apical membrane, the Michaelis
Menten analysis cannot yield the correct KM because of convolution of substrate pas-
sive permeability parameters into the calculated KM (Bentz et al., 2005). Therefore the
Michaelis Menten analysis peformed in these studies is not an accurate way to explain the
mechanism of eﬄux.
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Transport of drugs are studied in confluent cell monolayers but only single time point
measurements are taken and eﬄux ratios are calculated in either direction (Rautio et al.,
2006). Single time point data cannot be used to find best-fit values for kinetic parameters.
Continous time course measurements for transport are needed to quantitate the best fit
estimates for the elementary kinetic parameters that govern the mechanism of eﬄux.
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6. My Specific aims
The experimental aims of this thesis were designed to gain better insight into the
molecular mechanism of drug eﬄux by the human multidrug resistance transporter P-
gp. The kinetics of drug eﬄux and inhibition were studied using a robust kinetic model
for transport in a physiologically relevant cell culture system. This has led to a better
understanding of the structure-function relationship underlying the extrusion of a wide
variety of xenobiotics by this much-studied and clinically relevant membrane-associated
transporter protein. The specific aims are:
1. Generate consensus fits for elementary rate constants for association to, dissocia-
tion from and eﬄux by P-gp in addition to its functionally-relevant density on the
membrane. This will help us explain the fundamental rules of operation for this
transporter.
2. Determine the number of independent eﬄux-connected drug binding sites/pathways
in P-gp by studying the kinetics of inhibition using two P-gp substrates.
3. Understand the nature of cross talk between the drug binding sites/eﬄux pathways.
This will enable us to predict functionally relevant interactions within in the protein.
4. To find out if and how the presence of putative basolateral and apical transporters
in addition to P-gp, contribute to uptake and recycling of substrates in the cells.
5. Deconvolve the contribution of substrate and cell-related parameters in understand-
ing the relation between the IC50 values generated from the inhibition studies and
the aqueous dissociation constant of the inhibitor.
Once we can accomplish these, we would be one step ahead in unraveling the physiological
basis of the multidrug resistance phenomenon.
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7. Summary of research papers
Having presented the context and goals for our research, I embark on the journey of
telling a story about the structure and function of this intriguing protein that I have been
trying to put together for the past few years. A consensus understanding of P-gp is that
there are multiple substrate/inhibitor/modulator binding sites within the large binding
pocket in the inner apical monolayer (Lugo and Sharom, 2005a; Loo and Clarke, 2005b).
The main theme of the work presented here is to understand the salient features of
the P-gp mediated transport process. We apply the most rigorous kinetic analysis to the
transport and inhibition kinetics data obtained from the most physiologically relevant P-
gp expression system with the hope that the basic operating mechanism of this transporter
in vivo can be explained.
A confluent monolayer of Madine Darby Canine Kidney (MDCK)-II cells constitu-
tively over-expressing the human MDR1 gene that encodes P-gp in the apical plasma
membrane is used to measure transport of substrates radiolabeled with tritium or C14
over a period of 6 hours. The cells are grown in Transwell plates with a polycarbonate
membrane insert which serves as basement membrane for the cells to attach and grow. It is
a more complex expression system to analyze than conventional studies on re-constituted
systems like proteoliposomes, membrane vesicles, suspension cells or unpolarized adherent
cells. It has the advantage of studying P-gp in a tissue-like bed of cells which mimic the in
vivo environment, without the uncertainties of how purification and reconstitution affect
function.
To start with, transport experiments were done using amprenavir (HIV protease in-
hibitor which doesn’t show saturation during P-gp mediated transport), quinidine (Na+
channel blocker and prototype drug which has clinical relevance) and loperamide (an-
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tidiarrheal agent which showed 50% loss during transport).
Inhibition of P-gp mediated drug transport was studied using pair-wise combinations
of two substrates which had simultaneous access to P-gp. One of them is radiolabelled
and therefore acts as the substrate and the other one is unlabelled and thus acts as the
inhibitor-substrate. The radiolabelled drug can be added to either the basolateral or the
apical chamber and active transport is measured in both directions. To measure passive
permeation, P-gp is inhibited by a potent inhibitor GF120918 and trans/paracellular
movement of substrates is measured in either direction. The difference helps us quantify
the amount of P-gp mediated eﬄux and inhibition.
The data for the transport and inhibition experiments are subjected to a hierarchical
fitting algorithm which generates best fit values for each elementary rate constant for asso-
ciation to, dissociation from and eﬄux by P-gp for all concentrations of a particular drug
along with the eﬄux-active P-gp density. The details of the kinetic model are published
in Tran et al. (2004, 2005).
At this point I would like to briefly discuss a hurdle we faced while trying to identify
additional transporters contributing to flux of Loperamide and digoxin. It is generally
believed that membrane transporters mediate the transcytosis (eﬄux and uptake) of com-
pounds across the epithelial cells of the colon, kidney and liver, and across the endothelial
cells of the blood brain barrier, it has proven very difficult to identify which transporters
are involved in vivo (Lau et al., 2006). Over expression (based on increased mRNA) of a
particular transporter in a model cell line can identify its substrates and inhibitors (Dresser
et al., 2001; Shitara et al., 2006), but the extension of this knowledge to a physiological
model system which shows how the transporters function together has been lacking. This
issue serves as a backdrop for the third chapter. Kathleen Giacomini and her group had
worked extensively on the pharmacogenomics of organic anion and organic cation trans-
porters/transporting peptides and hence we chose the compounds primarily based on her
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research, (Dresser et al., 2001). There is not much information available on dog kidney
transporters and therefore we based our search on known transporters in mammalian (rat,
mice and human) cells.
Now that the basic premise and experimental set up for the experiments and analysis
is explained, I will summarize the highlights of each chapter in this thesis which has been
(or will be) submitted as an original research paper.
7.1 Summary of Paper 1
The first chapter attempts to evaluate the number of functional binding sites and eﬄux
pathways in a complex protein like P-gp and to explore the nature of the communication
between them. The fits from transport of amprenavir, quinidine and loperamide could
explain some of the key characteristics of P-gp function.
The same fitted value for the surface density of eﬄux active P-gp for all three drugs,
validated the fitting algorithm. The association rate constant of drug into the P-gp bind-
ing site, is lipid lateral diffusion controlled, which agrees with the drug binding site being
a large open vestibule in the inner apical membrane monolayer as suggested by structural
studies. A large association rate constant requires rapid dissociation back into the mem-
brane, for P-gp to maintain relatively weak binding for a very broad class of substrates. In
other words, for every substrate molecule pumped out, several thousands of them return
to the monolayer.
P-gp protects the cell against the cytosolic build-up of harmful compounds by main-
taining an eﬄux rate much faster than the rate of dissociation of the substrate from
the inner apical monolayer back into the cytosol. Substrates must be amphipathic and
therefore have large membrane/water partition coefficients to bind to P-gp within the
membrane in the first place. Amongst all the substrates binding to P-gp, only the one
bound at the moment when the ATP binding step is accomplished (Al-shawi and Omote,
35
2005; Loo and Clarke, 2005), is the one which gets eﬄuxed.
To probe the number of kinetically functional eﬄux pathways we conducted inhibi-
tion studies using pairwise combinations of substrates. These have shown that there is
competitive inhibition with high concentrations of either a substrate or an inhibitor. The
elementary rate constants fitted independently for each of the substrates alone quantita-
tively predicted the eﬄux curves assuming that binding at the “one site” was competitive.
This is a strong validation of our kinetic model and fitting algorithm. Remarkably, at low
concentrations of either the substrate and/or the inhibitor, we found no inhibition of the
substrate eﬄux, despite the fact that there was substantial eﬄux of the inhibitor. This
provides the first quantitative proof that the substrate and the inhibitor are being ex-
truded by multiple pathways through P-gp. Increasing the substrate concentration above
the “low” concentration caused the inhibition to become competitive, i.e. the inhibitor
became more effective. These results indicate that there are atleast 2 eﬄux pathways
through P-gp. There was no reason to believe that the eﬄux-connected binding sites and
pathways through P-gp are exclusive for any substrate. A rigorous analysis of a two site
binding model shows that binding of these substrates must be cooperative, either positive
or negative, based on the substrate-inhibitor pair.
We found that the density of eﬄux active P-gp, and the steady state passive perme-
ability coefficient for all three substrates is about 2-3 times larger than those reported in
Tran et al. (2004). Preliminary simulations testing the probability of escape of a substrate
after eﬄux predicted that only substrates released at the tip of the microvilli on the apical
membrane will have a reasonable chance of diffusing directly into the apical chamber. In
our assay only those molecules which appear directly in the apical chamber are counted
and this count is attributed to transport mediated by eﬄux-active P-gp or passive perme-
ability. Since the changes we see occur within the time scale of membrane recycling, we
hypothesized that change in microvilli dimension/morphology would affect the probability
36
of direct escape and, hence, the number of eﬄux active P-gp and the membrane area for
passive permeability. This implies that cells in culture do change and the result we observe
is really an example of the analytical power of our kinetic analysis to detect them.
7.2 Summary of Paper 2
For all concentrations of loperamide transport, we did not get consensus fits for the
elementary rate constants (Tran et al., 2005; Acharya et al. 2006). The low concen-
trations showed there was more transport than could be justified by setting eﬄux rates
for P-gp to infinity. This led us to believe that transporters other than P-gp contribute
to loperamide transport in the MDCK-hMDR1 cells. As the first step to evaluate this
possibility, additional transporters were modeled to compensate for the difference in the
nmoles transported by P-gp alone and the data. Based on this approach, we found kinetic
evidence that there is a basolateral transporter that helps loperamide get into cells much
faster than possible by its passive permeability.
We moved onto studying transport and inhibition of a clinically relevant P-gp substrate
digoxin (treats cardiac arrhythmias) which did not yield any fits at all. Digoxin has a
very slow passive permeability compared to quinidine, yet is a good inhibitor of quinidine
transport. This suggests that additional transporters help digoxin enter cells so that it can
compete with quinidine during transport. Using the same approach as before, we found
that a basolateral transporter causes digoxin uptake into cells and an apical transporter
helps it re-enter cells from the receiver side. Each of these transporters is fully inhibited
by GF120918 which necessitates using specific inhibitors to identify them.
In order to experimentally prove the presence and identity of these additional trans-
porters, we have attempted to screen members of the Organic anion/cation family of
transporters (Shitara et al., 2006) using more than 10 different compounds (good sub-
strates/inhibitors) for digoxin and loperamide inhibition experiments. This has resulted
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in no direct hits for OCT, OAT, OATP, URAT or MRP families of membrane transporters.
However this enables us to narrow down the list of possibilities. A future direction is to
find out whether loperamide and digoxin use the same or different basolateral transporter.
We also tried the typical cell concentration exclusion assay which shows benzbromarone
selectively inhibits digoxin accumulation but has no effect on the transport of digoxin. The
simplest hypothesis for explaining this is that benzbromarone reduces the cell’s cytosolic
volume, so less digoxin can accumulate, which would have no necessary change in trans-
port of digoxin, since it passes through the inner monolayer of the plasma membrane. This
suggests that cell concentration exclusion assays must be carefully controlled when used
with amphiphilic compounds eﬄuxed from a transporter whose binding sites are within
the plasma membrane, like P-gp.
7.3 Summary of Paper 3
The inhibition experiments showed that all combinations of substrate-inhibitor pairs
showed substantial inhibition of substrate transport and at concentrations near the IC50
(concentration of inhibitor that reduces drug transport by 50%) the inhibition between
substrates was simply competitive. For membrane transporters like P-gp, whose drug
binding site resides in the lipid bilayer, we suspected that the membrane may act as a
permeability barrier for the binding of drug since the drug is initially added in the extra
cellular space. Therefore passive permeability through the plasma membrane may affect
the correlation between the inhibitor’s dissociation constant with respect to water (KD,Aq)
and its IC50.
Our objective was to delineate the contribution of the substrate parameters that could
be convolved with the IC50, as was shown to be the case for the KM when the Michaelis-
Menten equations are used to analyze P-gp transport (Bentz et al., 2005). To address this
issue, simulations of substrate transport in the presence of “virtual inhibitors” based on
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the elementary kinetic parameters fitted in chapter 1 were used.
The simulations show that the IC50 over-estimates the dissociation constant of the
inhibitor to P-gp relative to the cytosol, KI,Aq, by a factor which depends upon probe
substrate kinetic parameters (partition coefficient into the membrane from cytosol, binding
constant to P-gp, passive permeability from both apical and basolateral sides into the cell)
and cell parameters (volume of apical membrane, P-gp eﬄux active density, area of the
transwell insert on which the cells grow). The smaller the passive permeability of the
substrate, the greater the overestimate of the inhibitor’s dissociation constant by its IC50
will be.
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P-gp expressed in a confluent monolayer of hMDR1-MDCKII cells has more than
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Abstract
The multidrug resistance transporter P-gp eﬄuxes a wide range of substrates and can
be affected by a wide range of inhibitors or modulators. Many studies have presented
classifications for these binding interactions, either within the context of equilibrium bind-
ing or the Michaelis-Menten enzyme analysis of P-gp’s ATPase activity. Our approach
is to study P-gp transport and its inhibition using a physiologically relevant confluent
monolayer of hMDR1-MDCKII cells. We measure the elementary rate constants for P-
gp eﬄux of substrates and study inhibition using pairwise combinations with a different
unlabelled substrate acting as the inhibitor. Our current kinetic model for P-gp has only
a single binding site, because a previous study proved that the mass action kinetics of
eﬄux of a single substrate were not sensitive to whether there are one or more substrate
binding and eﬄux sites. In this study, using this 1-site model, we found that with “high”
concentrations of either a substrate or an inhibitor, the elementary rate constants fitted
independently for each of the substrates alone quantitatively predicted the eﬄux curves,
simply applying the assumption that binding at the “one site” was competitive. On the
other hand, at “low” concentrations of both the substrate and the inhibitor, we found no
inhibition of the substrate eﬄux, despite the fact that both substrate and inhibitor were
being well eﬄuxed. This was not an effect of excess “empty” P-gp molecules, since the
competitive eﬄux model takes site occupancy into account. Rather, it is quantitative evi-
dence that the substrate and the inhibitor are being eﬄuxed by multiple pathways within
P-gp. Remarkably, increasing the substrate concentration above the “low” concentration,
caused the inhibition to become competitive, i.e. the inhibitor became effective. These
data and their analysis show that binding of these substrates must be cooperative, either
positive or negative.
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Introduction
The human multidrug resistance transporter P-glycoprotein, P-gp (1), is the product
of the hMDR1 gene, ABCB1, and is widely expressed in human epithelial tissue as a pro-
tection against xenobiotics. It is one of the 48 members of the ABC family of membrane
transporters within the human genome (2). The biological and clinical significance of
P-gp has been demonstrated through a large number of in vitro, preclinical and clinical
studies (3-10). A wide variety of in vitro expression systems have been used to study P-gp
structure and function: purified protein (11), lipid reconstitutions of purified P-gp (12-14),
plasma membrane vesicles (15), suspension or unpolarized adherent cells over-expressing
P-gp (16-18), and more recently polarized confluent cell monolayers (19-25).
A key question about P-gp, and any similar transporter, is how many functional bind-
ing sites and eﬄux pathways it contains, as well as the nature of the communication
between these sites. It is generally believed that the two transmembrane domains, TMD,
of P-gp form a large binding pocket (11, 14, 26, 27). Each TMD is composed of 6 trans-
membrane α-helices and the binding pocket appears to be within the interface between
α-helices 4, 5 and 6 of TMD 1 and α-helices 9, 10, 11 and 12 in TMD 2 (14). If P-gp
has more than one substrate binding site and each can lead to eﬄux, whether through a
common or a different route within P-gp, it will need to be analyzed by a multi-pathway
kinetic model. In this case, the next question is whether the pathways are independent or
cooperative.
The binding of substrates to P-gp has been assayed in many different ways, each of
which is consistent, at least in some studies, with multiple substrate/inhibitor/modulator
binding sites within the P-gp binding pocket. Lugo & Sharom (13) and Loo & Clarke (14)
have recently reviewed the current hypotheses about the number of binding sites on P-gp
and their possible interrelationships. There are many different proposals on both topics.
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To address these questions, we use a polarized MDCKII-hMDR1 confluent cell mono-
layer, which constitutively overexpresses P-gp in the apical plasma membrane. It has the
advantage of studying P-gp in a physiologically relevant expression system, without the
uncertainties of how purification and reconstitution affect function. It has the disadvan-
tage of being a more complex expression system to analyze. We believe that all expression
systems will be needed to elucidate the structure-function relationship of P-gp, however
the molecular parameters derived from P-gp transport from the confluent cell monolayer
system will be essential to understand the extent to which the purified systems or other
reconstituted expression systems predict the “native” function of P-gp. In particular,
the sensitivity which P-gp activity appears to be showing to lipid composition (28, 29)
makes the confluent cell monolayer, with an asymmetric lipid composition across the api-
cal plasma membrane, more likely to mimic the in vivo environment than proteoliposomes,
membrane vesicles, suspension cells or unpolarized adherent cells.
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Materials and Methods
Materials. Amprenavir and GF120918 were from GlaxoSmithKline (USA), loperamide
was from Sigma and quinidine was from Fisher Scientific. 3H-loperamide (10 Ci/mmole)
and 3H-amprenavir (21 Ci/mmole) were custom synthesized by Amersham Pharmacia
Biotech, England. 3H-quinidine (20 Ci/mmole) was from ICN Biomedical, Inc. USA.
Hoechst 33342 and rhodamine 123 was purchased from Invitrogen (Eugene, OR). DMSO
was from Sigma-Aldrich. Dulbecco’s Modified Eagle Medium (DMEM) was from Medi-
aTech, VWR. DMEM with 25 mM HEPES buffer, high glucose (4.5 g/L), L-Glutamine,
pyridoxine hydrochloride, w/o sodium pyruvate, and with phenol red was from Gibco. The
same medium without phenol red was used for transport experiments. Transwell 12-well
plates with polycarbonate inserts (0.4µm pore size and 12 mm diameter) were obtained
from Costar (Acton, MA).
Substrate Selection. Amprenavir, quinidine, and loperamide use were chosen because
they are good P-gp substrates, they are chemically unrelated and show different transport
and mass balance problems (23, 24). Hoechst 33342 and rhodamine 123 are commonly
used fluorescent substrates of P-gp (27).
Cell line and culture conditions. The Madin-Darby Canine Kidney II cell line over-
expressing human MDR1 (MDCKII-hMDR1) was purchased from the Netherlands Cancer
Institute (Amsterdam, Netherlands) (30). MDCK II cells were grown in 175 cm2 culture
flasks using DMEM with 10% fetal bovine serum, 1% L-glutamine and 50 U/mL penicillin,
50 mg/mL streptomycin at 37◦C in 5% CO2 atmosphere. Cells were split twice a week at
70-80% confluence in a ratio of 1:40, after at least 2 washes in PBS, and trypsinized with
0.25% trypsin/EDTA. All transport assays were done with cells from passages 30 to 55.
Cells were kept at 37◦C in 5% CO2.
Single substrate eﬄux assay. Cells were seeded in 12 well Costar-Transwell plates
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with polycarbonate membrane inserts at a density of 175,000 cells per insert and grown
for four days in culture medium. Cells were given fresh media 1 day after seeding. On the
day of the experiment, culture medium was removed and cells were pre-incubated for 30
minutes with either transport medium alone or transport medium with 2µM GF120918, a
potent inhibitor of P-gp. Eﬄux of a range of substrates across the confluent monolayer of
cells was measured in both directions, that is, apical to basolateral (A>B) and basolateral
to apical (B>A) in the presence and absence of GF120918. 0.5 mCi/mL 3H-amprenavir,
3H-quinidine, or 3H-loperamide was added to each respective substrate concentration to
allow quantitation of eﬄux from donor to receiver chambers. Lucifer yellow (100µM)
was added to the donor chamber to monitor integrity of confluent cell monolayer. 25 µL
samples were taken over a period of 6 hours, from both donor and receiver chambers into
96-well Lumaplates, dried overnight and the radioactivity counted by TopCount Model
9912 (Perkin Elmer, USA). The initial concentration measurement was taken at 6 min
after the addition of substrate in the first well (23, 24) and subsequent measurements
taken at multiple time points up to 6 hours for all experiments (24). After taking a 25 µL
aliquot, the plates were replaced in a shaker at a speed of 30 rpm, at 37◦C in 5% CO2.
Fluorescence of lucifer yellow (Ex max = 438nm, Em max = 530nm) was measured at
time zero from aliquots taken directly from the vials and compared to samples taken after
6 hours from both the basolateral and apical chambers into transparent bottom 96- well
plates. The fluorescence was analyzed using a SpectraMax microplate reader. Passive
permeability of lucifer yellow was always <20 nm/s over the 4 hr experiment.
Inhibition studies with two substrates. Cells were seeded and fed as described
above and on the day of the experiment culture medium was removed by aspiration. The
cells were then preincubated with the inhibitor/substrate in both chambers for 30 min.
Note that all inhibitors used here are also P-gp substrates. During the preincubation, half
the wells receive inhibitor solution without GF120918 (to study active transport) and the
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other half receives inhibitor solution with GF120918 (to study passive transport). After 30
minutes, the preincubation solutions were removed by aspiration and the labeled substrate
was added to the donor chamber, while refilling fresh inhibitor solution in both chambers,
again one half without GF120918 and the other half with it.
For quinidine eﬄux experiments using the fluorescent compounds Hoechst 33342 or
rhodamine 123 as the inhibitor, the same protocol was followed. Initially, Hoechst 33342
was dissolved in distilled water and rhodamine 123 was dissolved in absolute ethanol.
Cells were pre-incubated for 30 minutes with a solution of the fluorophor in transport
medium with and without GF120918 to study passive and active transport respectively.
The maximum ethanol concentration in the rhodamine transport media was <0.1%. Both
basolateral and apical chambers received the same pre-incubation solution. After 30 min-
utes, the preincubation solution was aspirated. Donor solutions contain appropriate con-
centrations of quinidine and both chambers received a fresh refill of the fluorophor, with
and without GF120918. Inhibition of quinidine eﬄux by either of these fluorophores was
studied over a period of 6 hours. The radioactivity from the aliquoted samples was read
using a TopCount Model 9912. Lucifer yellow was present in the donor solutions in all
cases. For the rhodamine 123 inhibition of quinidine eﬄux, lucifer yellow was used since
fluorescence from rhodamine 123 has a significant fluorescence spectra overlap. However,
the continuity of the kinetic trace of quinidine transport over 6 hours showed that the
monolayer remained intact.
Transport studies were done with rhodamine 123 following the same protocol as all
single substrate transport assays. The 25µL aliquots at specific time points were collected
in transparent bottom black-sided 96-well Costar plates and fluorescence from the aliquots
was read in a Cytofluor fluorescence plate reader at Excitation wavelength of 485nm and
Emission wavelength of 530nm with a bandwidth of 20nm.
Cell stability and substrate metabolism. We showed that the stability of the cell
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monolayer and plasma membrane with respect to passive and active transport was not
affected by the prolonged exposure times to amprenavir for at least 6 hr (data not shown;
24). It was also shown that metabolism or decomposition was insignificant for amprenavir,
quinidine and loperamide on this time scale using radio-HPLC (data not shown).
Numerical integrations. We used the stiffest integrator in MATLAB, ode23s, with
absolute and relative tolerances set between 10−8 and 10−10, depending upon the data
being analyzed (24). Other MATLAB integrators, while faster, were not accurate enough
at the later times of simulations. In data fitting, all concentration curves are simultane-
ously fitted, so that despite the fact that the A:B>A curve, i.e. substrate concentration
in the apical chamber when the basolateral chamber is the donor, is the most visually
striking, all curves contribute to minimizing the difference between data and simulated
curve. MATLAB fminsearch minimizes the coefficient of variation between the data and
the simulated curves. Further details can be found in (24) and (31).
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Mass Action Kinetic Model
Figure 1 is a cartoon of a confluent cell monolayer, showing the polarized MDCKII-hMDR1
cells, where the basolateral membrane is attached to the polycarbonate filters and P-gp
(upward arrows) expressed on the apical surface (32). The apical and basolateral chambers
are kept separate by the tight junctions. Active transport by P-gp occurs vectorally, with
substrate binding to a site on P-gp within the apical membrane inner monolayer and with
eﬄux into the apical chamber (6, 24, 27, 33). For many substrates, including those we
use, passive permeability is a significant fraction of total transport and is quantitatively
analyzed separately using a potent P-gp inhibitor, GF120918 (23, 24).
With the confluent cell monolayer system, we measure the concentration of substrate in
the apical chamber, denoted CA, and the basolateral chamber, denoted CB. However, the
concentration of substrate in the cytosol, denoted CC , and in the inner plasma membrane
in contact with the P-gp binding site, denoted CPC , cannot (yet) be measured rigorously
in real time. These internal concentrations are variables of a mass action model and fitted
by elementary rate constants for well-defined kinetic barriers, according to the measured
values of CB and CA over time (24).
Previously, we have fitted the P-gp elementary rate constants, the passive permeability
coefficients across the cell monolayer and estimates for partition coefficients for three P-gp
substrates: amprenavir (an HIV protease inhibitor), quinidine (a Na+ channel blocker),
and loperamide (an antidiarheal drug), chosen because of their very distinct behaviors as
P-gp substrates (24). P-gp was modeled by the simplest mass action reaction (8, 17, 24,
34), where the binding reaction takes place within the apical membrane inner monolayer
(27, 35):
T0 + Cpc
k1

kr
T1
k2−→ T0 + CA (9.1)
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where T0 is the empty transporter, CPC the substrate in the apical membrane inner
monolayer, T1 is the transporter bound by substrate and CA the substrate after eﬄux
into the apical chamber. The elementary rate constants which we seek to fit are: k1,
the association rate of the substrate to P-gp from the inner apical monolayer; kr, the
dissociation rate constant of substrate from P-gp back into the inner apical membrane;
and k2, the eﬄux rate constant of the substrate from P-gp into the apical chamber. We
calculated the binding constant of a substrate to P-gp, relative to being in the inner
apical monolayer, by the ratio of the fitted association rate constant, k1, and the fitted
dissociation rat constant, kr, i.e. KC = k1/kr, which is shown in Table 2 below. This
means that our binding constants are for the binding sites connected to the eﬄux pathway.
Since these binding constants are relative to the bilayer of the apical plasma membrane,
they must be multiplied by the appropriate partition coefficient to get the value relative
to the aqueous phase.
This reaction model has a single eﬄux pathway per P-gp. While it is known that P-gp
can bind more than one substrate molecule, Tran et al. (24) showed that with a single
substrate, since the rate constant of association, k1, was so large, the predicted eﬄux
curves were the same whether there was one or two or, presumably, more eﬄux pathways
in P-gp. Basically, if the binding site for one eﬄux pathway were filled by the substrate,
then “all” sites would be filled. Thus, the number of kinetically functional eﬄux pathways
can be probed only with the simultaneous usage of two, or more, different substrates.
The confluent cell monolayer is a challenging system to use when the aim is to obtain
the elementary rate constants for P-gp activity. However, we found for this system that
the standard steady-state Michaelis-Menten analysis for P-gp eﬄux, while commonly used
and typically yielding “good fits” to data, does not provide anywhere close to accurate
estimates for the Michaelis constant KM (31). This was because the passive permeability
across the cell membranes becomes convolved in the fitting of the KM value, with no ob-
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vious means to de-convolve the two parameters. This suggests that classifications of P-gp
transport inhibition based upon the classical Michaelis-Menten steady-state kinetic for-
malism in other expression systems, reviewed in (13,14), should be reevaluated to confirm
that the analysis is valid in the expression system used.
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Results
Amprenavir transport inhibited by quinidine. Figure 2 shows the passive and
total transport, which equals passive+active, of 100 µM amprenavir, initially in the donor
chamber across the MDCKII-MDR1 cell monolayers, inhibited by increasing concentra-
tions of the P-gp substrate quinidine. The passive permeability was determined in the
presence of 2 µM GF120918, a potent inhibitor of P-gp (23, 24, 36, 37). As expected for
a static passive barrier (23), when active eﬄux is inhibited with GF120918, the nmol of
quinidine transported is symmetric (i.e. the same for B>A and A>B) over time, as shown
by the closed symbols.
Without GF120918, P-gp increases total amprenavir transport in the B>A direction
and decreases of total transport in the A>B direction. Quinidine, a P-gp substrate,
was used as the inhibitor over the concentration range of 1-10 µM. Quinidine is pre-
incubated with the cells, in both chambers, for 30 min before the chambers are emptied
by aspiration and fresh quinidine is added to both chambers, along with radiolabelled
amprenavir added to the donor chamber. Thus, during the amprenavir transport, the
quinidine concentration is maintained close to the concentration initially added, despite
its own transport by P-gp. Clearly, the active transport of amprenavir is inhibited by
increasing quinidine concentrations.
Passive permeability is time dependent and is not affected by inhibitors.
Tran et al. (23) derived an exact equation for calculating the passive permeability coeffi-
cient at multiple time points, even when there is loss of substrate into the cells, e.g. due to
binding to intracellular components. Figure 3 shows the passive permeability coefficient
for quinidine over time in the presence of many amprenavir or loperamide concentrations,
as well as with GF120918. We have aggregated all passive permeability coefficients for
the for 0.1-5µM quinidine data in both directions, B>A and A>B, either alone or with
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inhibitors: amprenavir (50 and 100µM) or loperamide (0-10 µM). There are 34 different
data sets represented in this figure.
Clearly the passive permeability coefficient of quinidine increases for the first hour of
transport and is basically constant thereafter, where the arrow shows the steady-state
passive permeability coefficient across the confluent cell monolayer to be about 500 nm/s
in both transport directions. There is no significant dependence on inhibitor concentration
or the direction of transport. The same basic results were found for amprenavir passive
permeability coefficient in the presence of quinidine, which increased for the first 0.5 hr
before reaching the steady state (data not shown; 24).
For amprenavir and quinidine, this early time dependent increase in the passive per-
meability coefficient is not due to substrate “loading” into the cells, since there is no
significant loss of these substrates into the cells (data not shown; 23, 24). The change
occurs on the time scale of plasma membrane recycling and may be due to changes in
cell membrane area or cell microvilli morphology, as discussed below and in Tran et al.
(23). This is true because the passive permeability coefficient we calculate is per unit
area of insert of the Transwell apparatus, i.e. 1.13 cm2. For the fitting of P-gp transport,
this is not a problem, since the passive permeability is fitted independently, in order to
accurately calculate the active transport due to P-gp.
Loperamide’s passive permeability coefficient shows an asymmetric time dependent
change, with a greater increase for A>B than B>A, which appears to be coupled with its
absorption within the cells (data not shown; 23). However, the presence of quinidine did
not affect the time dependence of the change of loperamide’s passive permeability coeffi-
cient. We conclude that the presence of these inhibitors, at the concentrations used, do
not significantly affect the (time-dependent) passive permeability coefficients of substrates
through the confluent cell monolayer, which certainly implies that they do not affect the
bilayer structure significantly.
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Inhibition as measured by IC50. We began the analysis of substrate inhibition of
P-gp in a semi-quantitative way. Inhibition is typically represented by a curve showing
the reduction of P-gp specific transport at a particular time versus the inhibitor concen-
tration. In the B>A direction, P-gp transport is defined as the total nmol transported,
solid lines in Figure 2, minus the passive transport (+GF120918), dotted lines in Figure
2. This P-gp specific transport is normalized by dividing each value by the value in the
absence of inhibitor, yielding the fraction of P-gp transport. Thus, in the B>A direction,
the fraction of P-gp transport is 1 without inhibitor and decreases as the inhibitor con-
centration increases. The inhibitor concentration at which the fraction of P-gp transport
is 0.5 is defined as the IC50. In the A>B direction, this calculation would give negative
numbers, since P-gp inhibits total transport, so we used the absolute value to show the
fraction of P-gp transport.
We have collected our measured IC50 values in Table 1, measured after 2 hours of
transport, which looks basically the same as the curves calculated at 4 hours of transport.
It is important to note here that these times are chosen to focus on steady state P-gp
transport. For the substrates we use with the confluent cell monolayer, it requires 1
to 3 hours for binding to P-gp to reach steady state (24, 31). Using shorter times for
“initial rates”, predominantly measures just the passive permeability coefficients. This
semi-quantitative analysis has been done for each of the P-gp substrates we use and they
all can inhibit each other. For the transport of loperamide, inhibition by quinidine in the
B>A direction has an IC50 in the range of 5-8µM quinidine, but in the A>B direction,
inhibition seems to stall around a fraction of 0.5 for 10-30 µM quinidine, suggesting a
more complex interaction for loperamide with P-gp and the cells. Our IC50 values agree
with those published in Rautio et al. (25).
Ling and co-workers have made the case that Hoechst 33342 and rhodamine 123 bind to
different sites in P-gp and that rhodamine 123 binding can enhance the eﬄux of Hoechst
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33342 (15, 35, 38). Their studies used plasma membrane vesicles purified from P-gp
expressing CH*B30 cells. The membrane vesicles were assayed to be about 50% inside
out, so the fluorophores would not have to pass through a bilayer to reach the P-gp binding
site of these vesicles, i.e. within the cell’s inner monolayer of its plasma membrane. We
found that Hoechst 33342 inhibited quinidine with an IC50 which was about the same as
quinidine’s own IC50 for amprenavir and loperamide.
On the other hand, we found no inhibition of quinidine transport with up to 100µM
rhodamine 123. Tang et al. (39) claimed that there were fluorescence quenching artifacts
between Hoechst 33342 and rhodamine 123, which obscured the interpretations of the
studies by Ling and co-workers. We measured the transport of rhodamine 123 across
the confluent cell monolayer and found that its passive permeability coefficient is about
20 nm/s B>A and 10 nm/s A>B, i.e. more than an order of magnitude smaller than
quinidine, Fig. 2, and close to values reported by Tang et al. (39). This implies that it
would take over 24 hours for 50% transport to occur (23). This is not a reliable experiment
to follow with this cell line, since is it enough time for these cells to start overgrowing
themselves and obscuring the analysis. Interestingly, because the intracellular volume
of the entire confluent cell monolayer is so small, crudely estimated at 1µL (24), the
intracellular concentration would be predicted to be essentially the same as the donor side
concentration after 2 hrs, using the equations in Tran et al. (23), although this would be
difficult to prove.
We also found that the transport of rhodamine 123 was enhanced over passive per-
meability in the B>A direction, which would be expected if it were a P-gp substrate.
However, there was no inhibition of transport in the A>B direction, as would be expected
if it were not a P-gp substrate. The ambiguity of these findings will require additional
work, beyond the scope of this study.
These IC50 analyses show that each of the P-gp substrates we use can inhibit the other,
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but that proves nothing about the inhibition mechanism. Since we have shown for the
confluent monolayer system that the classical Michaelis-Menten analysis cannot predict
KM values to better than 1-3 orders of magnitude (31), there is no reason to assume
that the canonical textbook Lineweaver-Burke or Eadie-Hofstee curves for competitive,
uncompetitive and/or mixed competition are applicable to the confluent cell monolayer
system. Instead, we will pursue the question of mechanism with a rigorous analysis of the
mass action transport by P-gp.
Inhibition as measured by mass action kinetic analysis of a 1-site model
for P-gp. Our current P-gp transport model only has a single binding site for P-gp
(24, 31). However, writing a two-binding site model and fitting the data does not prove
that the model is correct, since more parameters will be available to fit the data. More
importantly, writing such a model and implementing it requires a clear idea of the most
important molecular parameters. With this in mind, here we are asking the simpler,
but essential, question of what kind of mechanisms can be tested by a one-site model.
This is a prerequisite to writing a minimal 2-site model, i.e. the one that captures the
important mechanisms with the fewest number of parameters. Since we use only P-gp
substrates, neither uncompetitive nor mixed-type competition are relevant, as defined by
the classical Michaelis-Menten analysis. Basically, there are two classical Michaelis-Menten
mechanisms and one other mechanism that can be tested against the data:
1. Competitive inhibition: Inhibitor replaces the substrate in “the single” P-gp bind-
ing site. This is the simplest case expected for combinations of substrates. When
transport data fits this model it does not prove that P-gp has only one binding site.
2. Noncompetitive inhibition: All P-gp bound initially to inhibitor is thereafter “in-
activated”, since inhibitor concentration is constant throughout our experiments.
This classical mechanism is simple to test, but it is rare with soluble enzymes. The
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transport data present here is nowhere near the predictions from this mechanism
and we will not consider it further.
3. No Inhibitor Effect: Despite substantial transport of the inhibitor, there is no effect
on substrate transport. Setting the inhibitor concentration to zero in the simulation
of substrate transport tests this mechanism, i.e. ignoring its presence and its known
P-gp mediated eﬄux. This is direct kinetic evidence of substrate and inhibitor
being eﬄuxed by independent pathways within P-gp, under the specific conditions
used. This caveat is very important, because it foreshadows our finding that the
“mechanism” will shift according to pathway occupancy. This mechanism has also
been called noncompetitive in the transport literature. We believe the nomenclature
used here is less likely to be confused with mechanism 2, above.
For this study, we have refitted all of the elementary kinetic parameters for single
substrate studies of amprenavir (AMP), quinidine (QND) and loperamide (LPM) using
new data. Since Tran et al. (24) described the kinetic analysis in detail, we will only
discuss the outcomes. The fitting algorithm developed in Tran et al. (24) finds all of the
possible values of the parameters {T(0), k1, kr, k2} which can best fit the data for each of
the substrate concentrations used. T(0) denotes the initial density of eﬄux active P-gp,
Not surprisingly, there are many different combinations which give essentially the same
best fits to the data, but they are clustered into a compact set, i.e. a seemingly random
collection of equally good fitting parameters within a closed area, which is a benchmark
for the validity of this kinetic analysis, as shown in Figure 4.
Figure 4 shows the final fitting for the best fit {T(0), k1 } pairs found in this study
for amprenavir transport, without any inhibitor. This different colored symbols denote
different amprenavir concentrations, from many separate experiments. The subset of
{T(0), k1} pairs within the blue box, which looks like a tilted trapezoid, fit all of the
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substrate data equally well and are called the consensus fits (24). The pairs outside of
the box only fit the data for some substrate concentrations. Values of the association rate
constant k1 > 1x1010M−1s−1 are excluded because that is at or near an upper bound for
substrate lateral diffusion through the bilayer (24). P-gp densities above 8000 P-gp/µm2,
or 0.01 M in the apical membrane (see footnote b in Table 2), are excluded because that
would require the plasma membrane be entirely covered by close packed P-gp (24). P-gp
densities below 1 P-gp/µm2, i.e. 4 orders of magnitude lower than the maximum, are
excluded as being too small. Otherwise, the fitting algorithm has no constraints.
The blue arrows in the “center of the box” show the values for each parameter which
are the values shown in Table 2, only to 1 significant digit. All of the fitted parameters
come from the “center of the box” of parameter values for the substrates tested, with a
range of about a factor of three for T(0) and the rate constants (see below). More precise
estimates are limited by experimental error and computational expense. These values are
quite adequate for our purposes here and are best fits for the data.
From Table 2, we see that the eﬄux active density of P-gp, T(0), is independent of the
substrate, which was a crucial test of the model and the fitting algorithm, since it should
not depend on the identity of the substrate (24). The association rate constant, k1, is also
independent of the substrate, which agrees with the open structure of P-gp for substrates
with similar molecular weights (24, 40).
On the other hand, the eﬄux rate constants, k2, the passive permeability coefficients in
both directions across the confluent cell monolayer, PBA and PAB, the binding constants
to P-gp from the inner apical monolayer, KC , and the partition coefficients, KPC , are all
substrate specific, as expected.
In the column showing the binding constants of the substrates to P-gp, there is also
shown an effective aqueous dissociation constant for each substrate, KD,Aq, which is cal-
culated as the inverse of the product of the binding constant times the partition coefficient
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to the liposomes, composed of 1/1/1::PE/PS/chol as the mimic of the inner apical mono-
layer. It estimates the aqueous concentration expected to give 50% binding to P-gp, in
the absence of inhibitor. This number is not near the steady state KM that would be
fitted using a standard Michaelis-Menten steady state analysis (31), because that analysis
doesn’t work for the confluent cell monolayer. These effective dissociation constants are
20-100 times smaller than the IC50 values shown in Table 1, showing that the IC50 cannot
predict the dissociation constant of the substrate when it is used as an inhibitor. For the
confluent cell monolayer, an IC50 is purely phenomenological and dependent upon many
factors besides the substrate binding constant, e.g. the substrate passive permeability.
This result will be elucidated in a separate study.
There are two significant differences between some of these values and those published
in Tran et al. (24). The first difference is minor, in that the binding constants for
loperamide and quinidine to P-gp found here are just above the upper bounds found in
Tran et al. (24). The values quoted here fit all of the data better.
The other difference is physiologically quite interesting. In Figure 4, the shape of the
consensus box for the {T(0),k1} pairs is somewhat different than that found in Tran et
al. (24), which yields roughly a 2-3 fold larger estimate for the center of the box value for
the density of eﬄux active P-gp, T(0), while the estimate for k1 is essentially the same.
In addition, the passive permeability coefficients for all three substrates are roughly 2-3
fold larger than reported in Tran et al. (24). The similar increase in two biophysically
“unrelated” parameters suggests a common mechanism. These differences do not affect
our analysis of the inhibition mechanism, but they are very important for the in vivo
activity of P-gp, which will be discussed below. This kinetic modeling is providing a high
resolution view of the transport data and can uncover differences which would be very
difficult to notice or prove otherwise.
For the inhibition experiments, the inhibitor is preincubated with the cells in both
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chambers for 30 min before the substrate is added to the donor chamber, with a refresh-
ment of the inhibitor concentration in both chambers at that time to ensure that transport
of the inhibitor does not change its concentration dramatically during the transport exper-
iment. A crucial part of the fitting process is using the passive permeability coefficients at
all time points to correct the total transport for the contribution of passive permeability.
As explained in Tran et al. (24), this correction must be done within the mass action
equations for transport, rather than simply subtracting the nmol transported passively
from the total nmol transported, which neglects transport reversibility. All these passive
permeability coefficients increase in time until a steady state is reached, as shown in Figure
3 for quinidine. For fitting active transport, we use the individual values for each time
point, e.g. up to 1 hour for quinidine, until the steady state is reached. Thereafter, the
average value within the steady state period is used, as shown in Figure 3 for quinidine
by the arrow at about 500nm/s. This approach avoids fitting the noise of the passive
permeability coefficient (24).
Competitive Inhibition versus No Inhibitor Effect. We can now move to the
mechanism of inhibition of P-gp eﬄux by P-gp substrates. These data will be shown
as the substrate concentration over time in both chambers, since this is the form of the
data actually being fitted. The different concentrations are labeled in the figures by a
short notation. For example, A:B>A is read as the concentration of substrate in the
Apical chamber when the Basolateral chamber is the donor and the Apical chamber is the
receiver.
Figure 5 shows a sample of the data and fits for the P-gp mediated transport of
quinidine when amprenavir is the inhibitor. Figure 5A shows 0.3µM quinidine transport
in the presence of 100µM of the inhibitor amprenavir. Data are shown by the symbols with
error bars defined by the standard deviation of triplicate measurements. All simulations
used the single substrate parameters shown in Table 2, i.e. there is no fitting of these data
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with inhibitor. The solid lines show the case where binding to the “single P-gp site” is
competitive, using the binding constants shown in Table 2. The dashed lines show the case
where there is no inhibitor effect, i.e. the concentration of amprenavir is set to zero in the
simulation of the dashed line in the figure. This is equivalent to amprenavir following a
different eﬄux pathway within P-gp than the one used by quinidine. Clearly, competitive
inhibition fits the data much better than the no inhibitor effect curve. Note that the color
of the data, blue for basolateral and red for apical, must match the color of the simulation
curves for the data to fit. Likewise the data symbols must match, with squares for B>A
flux, where the basolateral chamber is the donor, and triangles for A>B flux, where the
apical chamber is the donor.
Competitive inhibition is the simplest expectation for two substrates. This does not
prove that P-gp has only one eﬄux pathway. Doubling the number of “competitive”
pathways in P-gp would have little effect on the total transport because one of the most
important fitted parameters is the product of the eﬄux rate constant and the density
of eﬄux active P-gp, k2T(0), which is the equivalent of Vmax in the language of the
Michaelis-Menten analysis (24). This parameter is very tightly fixed (24), so that if we
simply proposed that P-gp had twice the number of pathways, the eﬄux rate constant k2
would become half as large as that shown in Table 2. This makes sense, since the overall
substrate eﬄux would be the same in both cases and that is what is being fitted.
Figure 5B shows the data and fits for the P-gp mediated transport of 0.3µM quinidine,
now in the presence of only 50µM of the inhibitor amprenavir, i.e. half the concentration
as in Figure 5A. If quinidine and amprenavir still competitively bind to the “single P-gp
site”, then the solid curves should fit the data just as well as the case above. The fact
that less amprenavir and more quinidine would be bound is taken into account by the
equations for competitive inhibition. Remarkably, the data is fitted better by the case of
no inhibitor effect. It is important to pay attention here to the donor side curves, B:B>A
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and A:A>B, where the no inhibitor effect simulations predict a slower loss of quinidine
from the apical donor side than for the basolateral donor side, which is what the data
shows. The competitive inhibition simulations predict the same rate of quinidine loss
from both donors, which was what was observed in Figure 5A with the larger amprenavir
concentration, but not with 50µM amprenavir.
Before continuing, it is important to explain that we decided to use this plot format
because it can prove mechanism most compactly. The conventional plot of nmol trans-
ported per µM of inhibitor will show inhibition only at adequately high concentrations,
regardless of whether inhibition is always competitive or there is no inhibitor effect at
the low concentrations. If binding is competitive, then inhibition will only occur when
enough inhibitor had bound to replace some bound substrate. However, if the mecha-
nism transitions from no inhibitor effect to competitive once the “amounts bound” exceed
some limits, which is the case here, then the conventional curve will show no inhibitor
effect until the mechanism shifts over to competitive inhibition. The qualitative inhibition
curve will look the same, except that the “binding constant” of the inhibitor will appear
weaker than it actually is. In order to prove that no inhibitor effect occurs, it must be
shown that the amount of inhibitor needed to cause competitive inhibition is greater than
that predicted by the independent binding constants. The plot format we use shows this
comparison simply and directly.
We will see below that there is substantial amprenavir transport by P-gp under similar
conditions, thus this P-gp mediated transport of amprenavir must be through a different
pathway than that used by quinidine here. All of the combinations of concentrations
shown in Table 1 have been analyzed. The data presented in the figures were picked to
show roughly the minimal concentrations needed to provide competitive inhibition and the
maximal concentrations allowed to show no inhibitor effect. The message is simple. When
the substrate and inhibitor concentrations are both small enough, there is no inhibitor
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effect, despite the fact that there is P-gp mediated transport of the inhibitor transport.
For example, Fig. 6A below, 50µM amprenavir shows substantial transport in the presence
of 2µM quinidine, i.e. 7 times more quinidine than in Fig. 5B.
The next result is even more interesting. Figure 5C shows the data and fits for the P-gp
mediated transport of 3µM quinidine, i.e. a 10-fold increase of the substrate concentration
with the same 50µM of amprenavir as the inhibitor. Here the best fit is back to compet-
itive inhibition. So when amprenavir is relatively saturating of P-gp, 100µM versus 50
µM, or quinidine is relatively saturating of P-gp, 3µM versus 0.3µM, then the inhibition is
competitive. An increase in substrate concentration, 0.3 to 3 µM quinidine, causes the in-
hibitor, 50 µM amprenavir, to transition from no inhibitor effect to competitive inhibition.
This novel result proves that the binding sites for eﬄux pathways are cooperative, as shown
in the Appendix-Supplementary Material (http://pubs.acs.org/subscribe/journals/
bichaw/suppinfo/bi060593b/bi060593bsi20060919_032146.pdf). So we are seeing a
mixing of mechanisms driven by binding site occupancy.
Here we want to show other substrate combinations to determine the generality of this
observation. Figure 6 shows the data and fits for the P-gp mediated transport of am-
prenavir when quinidine is the inhibitor. Figure 6A shows the data and fits for the P-gp
mediated transport of 50µM amprenavir in the presence of 2µM of quinidine. The best
fit is for no inhibitor effect. So even 2 µM quinidine is not enough to yield competitive
inhibition. However, as shown in Figure 6B, the P-gp mediated transport of 50µM am-
prenavir in the presence of 5µM of the inhibitor quinidine is mostly competitive. So the
transition from no inhibitor effect to competitive inhibition is gradual rather than abrupt,
at least on a population average.
We now turn to loperamide, which appears to have a more complex interaction with
these cells than quinidine and amprenavir (23, 24). Figure 7 shows the data and fits for the
P-gp mediated transport of quinidine when loperamide is the inhibitor. Figure 7A shows
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the data and fits for the P-gp mediated transport of 1µM quinidine in the presence of 2µM
loperamide. The best fit is for no inhibitor effect. Figure 7B shows the data and fits for
the P-gp mediated transport of 3µM quinidine in the presence of 10µM of the inhibitor
loperamide. The best fit is competitive. We also studied the P-gp mediated transport of
50 and 100µM amprenavir when loperamide is the inhibitor. There was no inhibitor effect
with 50µM amprenavir inhibited by 1 µM loperamide and competitive inhibition with
2-10 µM loperamide. The transport of 100 µM amprenavir was competitively inhibited
by 1-10 µM loperamide (data not shown).
Loperamide is inhibited by quinidine, however the inhibition was incomplete in the
A>B direction, Table 1. Complete inhibition of P-gp mediated transport of loperamide
can only be achieved with very high quinidine concentrations, >20µM, where there is
little P-gp mediated transport (data not shown). This suggests that loperamide has an
additional interaction with these cells and/or P-gp beyond those that are well modeled for
amprenavir and quinidine, as noted previously in Tran et al. (24). Our current hypothesis
is that there is another transporter in the basolateral membrane, which admits loperamide
and which is completely inhibited by GF120918. Since the cell line used is canine kidney
epithelial, there are many candidates (41). We can say that quinidine and amprenavir
have no significant interaction with this putative transporter, at any concentration used
(data not shown). When loperamide is an inhibitor, the putative transporter only makes
more certain that the preincubation achieves steady state in loperamide. We will present
the inhibition of loperamide transport by these other P-gp substrate in a separate paper,
since this is outside the scope of this work. The bottom line is that the existence of this
putative loperamide transporter does not affect our conclusion that P-gp has multiple
pathways, at least for amprenavir and quinidine.
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Discussion
It is known that P-gp can bind more than one substrate at a time (13, 14). However,
Tran et al. (24) showed that the eﬄux kinetics of a substrate, without any inhibitor, was
predicted to be the same whether each P-gp had one or two eﬄux binding sites. Because
the association rate constant to P-gp was so large, effectively lipid lateral diffusion con-
trolled, if one site was occupied, then all sites were occupied. Equilibrium binding and/or
ATPase activity could not have predicted this. To understand the activity of P-gp eﬄux
with the confluent cell monolayer, the mass action kinetics of eﬄux must be studied di-
rectly and rigorously, i.e. not with the steady-state Michaelis-Menten equations (31). In
order to determine the number of eﬄux pathways of P-gp, it is necessary to use more than
one substrate at a time.
Inhibition of P-gp by its substrates and modulators has been intensely studied, as
reviewed by Lugo & Sharom (13) and Loo & Clarke (14). From many assays, including
transport, it has been found that some pairs of substrates do not compete with one
another, at the particular concentrations studied, which has been called a noncompetitive
interaction. We define this mechanism as no inhibitor effect, so as not to confuse it with the
classical noncompetitive inhibition mechanism for enzymes. This observation lent support
to the work of Ling and co-workers, who have made the case that Hoechst 33342 and
rhodamine 123 are P-gp substrates which bind to different sites in P-gp and that rhodamine
123 binding can enhance the eﬄux of Hoechst 33342, suggesting distinct pathways through
P-gp (15, 35, 38; see also 27 and 39). Additional quasi-independent pathways have been
proposed (42). Of course, there may be other binding sites for modulators of P-gp activity
that do not lead to eﬄux of that modulator.
For single substrates, we show binding constants to P-gp from the inner apical mono-
layer in Table 2. In fact, these binding constants were calculated from ratio of the fitted
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values of the association rate constant k1 and the dissociation rate constant kr, from P-gp
back into the inner apical monolayer, i.e. KC = k1/kr(M−1). This means that the binding
constants we measured are for the binding sites of the eﬄux pathways.
Our analysis yields a fairly simple picture of substrate binding and eﬄux for P-gp, at
least for quinidine and amprenavir, as well as inhibition by loperamide, a trio of drugs
chosen solely because of their different behaviors as P-gp substrates (23, 24). Using
the elementary rate constants fitted for these substrates alone, we found that at “high”
concentrations of substrate and/or inhibitor, the substrate eﬄux curve was fitted very
well with the sole assumption that substrate and inhibitor competed for the “single” P-
gp binding site. The fit does not imply that each P-gp has only one binding site, but
only that all sites behave as though they are independent at the substrate and inhibitor
concentrations used.
At low concentrations of substrate and inhibitor, the eﬄux of the substrate was un-
affected by the presence (and eﬄux) of the inhibitor. Under these conditions, we found
that the eﬄux of the substrate was still quantitatively predicted using the elementary rate
constants fitted for each of the substrates alone, with the sole assumption that inhibitor
did not bind to the substrate’s “single site”, i.e. it must use another site and eﬄux path-
way. This proves that P-gp has two or more eﬄux pathways. The gradual transition from
no inhibitor effect to competitive inhibition as the concentration of either substrate or
inhibitor increases suggests that both substrate and inhibitor can bind to all the eﬄux
connected binding sites, as their individual binding constants prescribe. It has been pro-
posed that these binding sites are flexible or to some extent inducible (43). We will need
to build the 2-site eﬄux model to fit and simulate the gradual transition from no inhibitor
effect to competitive inhibition to better understand the mechanistic implications of this
finding.
It is very important to mention that the ability of the one site model to fit the compet-
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itive inhibition data is a strong validation of our kinetic model and fitting algorithm. The
analysis presented in Tran et al. (24) is rather complex within the field of P-gp transport
kinetics. That was a consequence of our belief that a clear understanding of P-gp eﬄux
activity in vivo could only come from applying the most rigorous kinetic analysis to the
most physiologically relevant expression system. The fact that the density of eﬄux active
P-gp in the cell membrane was found to be independent of substrate type was required if
the model and the fitting algorithm were valid. The lipid lateral diffusion controlled value
of the association rate constant, k1, was also independent of substrate type, which agrees
with the predicted openness of the structure of P-gp within the plasma membrane (24,
40).
However, since the fitted value of k2 is different for each substrate, it could be argued
that the parameter we fit is not really the eﬄux rate constant from P-gp, but rather
represents a distinct and unknown barrier for each substrate. We just fit a parameter in
an equation, which does not prove the parameter is the claimed rate constant for P-gp
eﬄux. There are good reasons why our assignment of k2 to the eﬄux rate constant of
P-gp is reasonable (24), but that does not eliminate the question. Since we are fitting 3
rate constants and a P-gp membrane density simultaneously, such an argument must be
constantly checked against the data.
The fact that the single substrate parameters for amprenavir and for quinidine can
quantitatively fit the competitive inhibition data would be hard to explain if the fitted k2
were not the P-gp eﬄux rate constant for each substrate. It is nearly certain now that
the fitted k2 must come from the same barrier for all three substrates. The fitting process
is so blind and so exhaustive, leaving no potential fit undiscovered, that we are now far
more confident that the k2 we fit is the eﬄux rate constant for P-gp.
Spoelstra et al. (16) found evidence of inhibitor concentration affecting the “mecha-
nism” of P-gp eﬄux. They studied the interaction of daunorubicin with verapamil, both
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P-gp substrates, in multidrug resistant cell lines grown as a monolayer on plates and fit-
ted their data with a Michaelis-Menten steady-state model for no inhibitor effect, using
our terminology. However, at a higher daunorubicin concentration there was a shift away
from this model. They proposed two daunorubicin binding sites in P-gp, with verapamil
binding to the weaker site, so that high concentration of daunorubicin would be required
to competitively inhibit verapamil transport.
What do our kinetic findings about transport tell us about the interaction between
the eﬄux binding sites, i.e. cooperativity? The key observation was that increased sub-
strate concentration causes the inhibitor to increase its competitive inhibition of substrate
transport. Without inhibitor, increased substrate concentrations do not “inhibit” trans-
port in any way, as shown here and in Tran et al. (24). A single binding constant and
a single eﬄux rate constant fits all the substrate concentration curves. Of course, this
must not be confused with the fact that P-gp mediated transport does become saturated
with increased substrate concentration, thus making the fraction of total transport due
to P-gp smaller relative to passive permeation. The transition from no inhibitor effect to
competitive inhibition means that the eﬄux of substrate is less than it would have been
without inhibitor.
Basically, the increased substrate concentration must increase the efficacy of the in-
hibitor either through the binding constants, KC = k1/kr, or the eﬄux rate constants, k2.
Obviously, an increase in substrate concentration must cause an increase in the amount
of substrate bound. If the eﬄux rate constants, k2, are responsible for the transition
to competitive inhibition, then bound substrate must inhibit the flow of other substrate
molecules or enhance the flow of inhibitor molecules through the other eﬄux pathways,
relative to having inhibitor bound to those other eﬄux binding sites. How this could hap-
pen, when substrate alone does not show the same effect, is very unclear. Any proposed
mechanism along these lines will require a complex feedback loop and there is no data, or
84
theory, supporting such a concept at this time.
It is easy to believe that cooperative binding between the two, or more, eﬄux binding
sites could cause the transition from no inhibitor effect to competitive inhibition with in-
creased substrate concentration. To prove this, we have carried out a rigorous and general
analysis of the 2-site binding model in the Appendix (which is posted in Supplementary
Material).
Interestingly, many different combinations of positive and/or negative cooperativity
can predict the increased inhibitory effect with an increased substrate concentration. This
is an important finding in order for the binding model to be robust, since all the different
pairs of P-gp substrates may have very different interactions within the binding pocket,
see also (14).
While there has been much speculation about P-gp eﬄux cooperativity based upon
equilibrium binding and/or ATPase activity, this is the first prediction about binding based
upon eﬄux kinetics alone, insofar as we are aware. In fact, since our binding constants are
obtained from eﬄux kinetics, they are for the eﬄux binding sites of the active P-gp in the
plasma membrane. While the binding model analyzed here is “only” 2-site, which entails a
fair amount of complexity, the rigorous analysis of a 3 or 4 site binding model would likely
reach the same conclusion. It is interesting that recently published theoretical structures
for P-gp only proposed two or three binding sites, while the binding pocket appeared to
be fairly “crowded” with transmembrane helices (44, 45), providing ample possibilities for
cooperativity.
This study provides important guidance for our construction of the 2-site transport
model for P-gp, since we now know that cooperativity must be part of that model. The
cooperativity terms in the model will not just be extra parameters for fitting the data, but
rather will be required to fit the transition between no inhibitor effect and competitive
inhibition observed for the substrates used here.
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Now we can discuss our finding that two of the fitted parameters changed from values
published in (24). We now find that the density of eﬄux active P-gp, T(0), is about
2-3 times larger and that the steady state passive permeability coefficient for all three
substrates is about 2-3 times larger than the respective values reported in Tran et al.
(24), as shown in Table 2. We note that k1 and k2 did not change significantly, strongly
suggesting that the change is not in P-gp, per se. Cells in culture do change or respond to
subtle changes in support composition (32) and the result we observe is really an example
of the analytical power of our kinetic analysis. We know which parameters changed and by
how much, which would not be possible using, for example, the Michaelis-Menten steady
state equations (31).
Although the confluent cell monolayers were cultured the same way in all studies, to
the extent possible, there was a hiatus of about a year between the end of data acquisition
for Tran et al. (24) and the beginning of the studies reported here. The parameter
values in Table 2 have been found consistently, e.g. Figure 3 incorporates 17 separate
experiments completed over the course of more than a year. The fact that the P-gp eﬄux
active density changed and that the passive permeability coefficients changed, and both
changes are about the same magnitude, suggests that the simplest explanation will be one
which affects both “equally”. An increase in the expression level of P-gp is unlikely to
change passive permeability coefficients, and vice versa.
The simplest explanation which ties the density of eﬄux active P-gp with the passive
permeability coefficient is the random walk the substrate must make between the microvilli
subsequent to leaving the outer apical monolayer, either by eﬄux by P-gp or by permeation
through the bilayer or tight junction. Figure 8 shows a roughly scale model cartoon of a
pair of microvilli, which are about 10 µm high, 1 µm in diameter and separated by 1µm.
By definition in the kinetic model, the P-gp which are eﬄux active are those which send
their substrate directly into the apical chamber, where it equilibrates “instantly” between
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the sampling volume of the apical chamber and the outer apical monolayer, according to
the partition coefficients. Tran et al. (24) found that the surface density of eﬄux active
P-gp was probably 10-20 times smaller than the total P-gp estimated in Ambudkar et
al. (47) for a related cell line. While the cell lines were not identical and expression
levels for our line have not been quantitiated, we felt the difference was significant and
we hypothesized that only those P-gp at the tips of the microvilli will be eﬄux active
for our fitting. This does not mean that the rest of the P-gp do not eﬄux, but rather
the random walk of substrate released from P-gp into the aqueous space at the base of a
microvillus will almost certainly encounter the same or a neighboring microvillus rather
than escaping non-stop into the apical chamber. Absorption back into the outer apical
monolayer and flip-flop into the inner apical monolayer would put the substrate back to
where it started and the cycle would have to be restarted. Only those substrate molecules
that are released from P-gp at or near the tips of the microvilli would have a reasonable
probability of escaping directly into the apical chamber. Our current data increases the
eﬄux active P-gp to about 3-10 times smaller than that estimated in (47) for the related
cell line.
The 2-3 times larger steady state passive permeability coefficient for all three substrates
reported here, relative to values reported in (24), can be explained by the same hypothesis.
Recall that the passive permeability coefficients are calculated relative to the surface area
of the plastic inserts the cells are grown on, i.e. 1.13 cm2, since we cannot know the true
membrane surface area (23, 24). A change in the cell monolayer surface area that can
directly release substrate into the apical chamber will change the passive permeability
coefficient we report. Obviously, microvilli morphology can change this true membrane
surface area and the changes we see occur on the time scale of membrane recycling,
e.g. Fig. 3 (48). Thus, in Figure 8, the diffusion pathway shown will also apply to a
substrate released at the base of the microvilli by passive diffusion through the bilayer or
87
tight junction. Changes in the morphology of the microvilli would have to change both
the number of eﬄux active P-gp and the passive permeability. It is difficult to conjure
another mechanism that explains both changes so parsimoniously. If this hypothesis is
correct, then the morphology of the microvilli is an important component of P-gp’s in vivo
activity, as well as for this cell line.
We have performed a simple test calculation for this hypothesis using a very simple
model for the aqueous space between adjacent microvilli. We have simulated a random
walk away from a square well sunk into an infinite plane, 1µm on all 4 sides and 10µm
deep. The question is whether a particle released from the side of the well, like the side
of the microvilli, will escape to the apical chamber or be reabsorbed into the wall or
the plane. The test particle was released 1nm from the wall, or the plane, and its 3D
random walk was followed until it hit another wall of the square well, the infinite plane
or escaped into the apical chamber by reaching 10µm from the top of the plane. To get
reliable statistics, we examined 108 test particle releases. Relative to the escape frequency
from the plane 1um away from the edge of the well, like the tip of the microvillus, the
probability of escape starting from the top edge of the well, midway between the corners
of the well, was just 0.38. Particles which had entered into the well had a much smaller
chance of eventually escaping than particles that never entered the well. This probability
of escape was reduced nearly exponentially as the test particle was released further down
the side of the well, mimicking being released from the sides of the microvilli, to 0.013
when release was 1µm into the well and to 0.00083 when release was 2µm into the well.
Escape from the bottom of the well, like the release point shown in Figure 8, was at least
8 orders of magnitude less probable, i.e. not one out of 108 released particles escaped. It
is a highly simplified model of escaping from the microvilli without being reabsorbed, but
it shows that the basic hypothesis is physically sound.
Conclusions: We have three general conclusions about P-gp eﬄux kinetics. The
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first is that the specific mechanism of binding and inhibition does not change the eﬄux
kinetics of P-gp by a large amount, about 2-fold at most, as shown in Figures 5-7. The no
inhibitor mechanism predicts greater eﬄux by P-gp than does the competitive inhibition
mechanism, as it must. Based upon our findings and the literature, it seems that the
general model for P-gp substrates moves from no inhibitor effect to competitive inhibition
as P-gp becomes saturated with either substrate or the inhibitor. However, this difference
appears not produce much selective pressure on P-gp to extend the concentration range
wherein the no inhibitor effect operated and, thus, where the kinetics of substrate eﬄux
would be somewhat larger.
The second general observation concerns the long-standing speculation about whether
P-gp eﬄuxes the substrate into the apical aqueous space or delivers the substrate in the
outer apical monolayer as a flippase, followed by passive diffusion into the aqueous space,
(14, 49). Our kinetic model for P-gp has eﬄux into the apical aqueous space with an
instantaneous equilibration between the apical chamber and the outer apical monolayer,
based upon the estimated partition coefficients, Eq. (1) and (24). If we had chosen to
follow the flippase model, then what was delivered to the outer apical membrane would
be instantaneously equilibrated with the apical aqueous chamber. The assumption of
instant equilibration was based upon data showing that similar types of molecules bind
to liposomes very rapidly, within seconds, compared with the kinetics of eﬄux over hours
from the confluent cell monolayer (24). Explicitly including the kinetics of substrate
permeation from the outer apical monolayer to the aqueous space of the apical chamber,
or vice versa, would have doubled the number of mass action differential equations needed
to fit the data, in order to fit these on and off rate constants to the bilayer. That would
have been computationally too expensive.
Loo & Clarke (14) are quite right that determining which of these two mechanisms
P-gp follows will require very rapid stopped-flow kinetic techniques. However, if P-gp
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eﬄux is into the aqueous space, due to the initial ATP binding or its hydrolysis, then the
mechanism of release is likely passive diffusion of the substrate out of the binding pocket
subsequent to a decrease in its binding constant to P-gp. That means that after leaving
the extracellular domain of P-gp, the “eﬄuxed” substrate will be within a nanometer,
or so, of the bilayer. The random walk back to the bilayer would be common, and not
take long, according our simple random walk simulation described just above. Seen from
the perspective of kinetics, there is very little difference between the two mechanisms.
Our kinetic model fits the eﬄux data assuming a maximal recycling of substrate, where
it is free to rebind to the outer apical monolayer as soon as it leaves P-gp. This shows,
regardless of whether it is a flippase or a transporter, that P-gp protects the cell in part
by keeping the xenobiotics occupied at the plasma membrane, as well as by facilitating
their diffusion away from the apical bilayer of the cell.
Our fitted rate constants support this view of how P-gp does its job. Comparing the
eﬄux rate constant, k2, with the dissociation rate constant, kr, shows that bound substrate
is 104 - 105 times more likely to be released back into the inner apical membrane than being
eﬄuxed into the apical aqueous compartment. Since the association rate constant, k1, is so
large, rapid dissociation back into the membrane is required for P-gp to maintain relatively
weak binding for a very broad class of substrates. This means that the selective pressure
on P-gp, with respect to keeping xenobiotics out of the cytosol, is to keep k2 larger than
the passive permeation rate of the substrate through the inner apical monolayer into the
cytosol. We do not know this permeability coefficient, but using the overall permeability
coefficients shown in Table 2, we estimate the rate constant for release into the cytosol is
at least an order of magnitude smaller than the eﬄux rate constants, k2, shown in that
Table.
The third general observation concerns the similarity of eﬄux mechanism between P-
gp and the related multidrug resistance-related transporters, MRPs. Borst et al. (50)
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review the current transport data of MRPs and favor a model in which the binding pocket
can bind more than one ligand, allowing cooperative interactions between ligands, rather
than the alternative model of requisite co-transport of two different ligands. The similarity
with P-gp mechanism is clear.
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Substrate 
(conc. range) 
Inhibitor 
(conc. range) 
IC50 Comments 
Amprenavir  
(50 & 100 uM) 
Quinidine 
(0-20 uM, n=9) 
 
2-5 uM 
B>A was inhibited 
slightly more 
 than A>B  
Quinidine 
(0.1-3 uM, n=4 a) 
Amprenavir  
(0, 50 & 100 uM) 
 
~100 uM 
Only 2 AMP 
concentrations tested 
since the solubility 
limit reached above 
100uM 
Quinidine 
(0.1-5 uM, n=5) 
Loperamide 
(0-10 uM, n=8) 
 
5-8 uM 
 
Quinidine 
(1-5 uM, n=4) 
Hoechst 33342 
(0-10 uM, n=5) 
 
2-5 uM 
Hoechst 33342 
inhibits at the same 
concentration range 
as quinidine 
Loperamide 
(1-5 uM, n=4) 
Quinidine 
(0-30 uM, n=10) 
 
 B>A:  5 uM 
A>B:  ≥5-20 uM 
 
Fraction inhibition 
stalled at about 0.5  
 
Figure 9.1: Paper 1: Table 1 - IC50 ranges for P-gp substrates.
Legend for Table 1.
a n= number of different concentrations tested from the sequence of 0, 0.1, 0.3 , 1, 2,
3, 5, 10, 20 and 30 µM.
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Figure 9.2: Paper 1: Table 2 - Fitted Parameter Values with Single Substrate Experiments.
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Legend for Table 2.
a The product of k2T(0) is very rigorously fitted by the first step in the algorithm and
the values shown were fixed by at least the first 100 best fits, which all has the same co-
efficient of variation, CV, i.e. these are robust fits at each concentration. For loperamide,
the fits were taken from the higher concentrations only, ≥ 5µM. Lower concentrations
did not yield so many stable fits, although the integrated curves using these parameters
look reasonable. As mentioned in the Results section, loperamide fits require a basolateral
transporter, which is inhibited by GF120918, i.e. the P-gp inhibitor.
b The “center of the box” eﬄux active concentration of P-gp within the inner apical
monolayer, as shown in Figure 4 for amprenavir. These units can be converted to a more
typical form, assuming a 2nm lipid monolayer thickness for the acyl chain region. T(0)
(P-gp/µm2)=0.8*T(0) (µM, inner apical monolayer)=160 P-gp/µm2. The ratio of apical
membrane to the insert cross section area is irrelevant, since it cancels out in the calcula-
tion.
c Center of the box estimate for the association rate constant k1. As shown for amprenavir
in Figure 4, the range was k1 = (1 − 10)x109M−1s−1. For quinidine and loperamide the
range was broader, k1 = (0.2− 10)x109M−1s−1(data not shown; 24).
d Center of the box estimate for the eﬄux rate constant k2, from P-gp into the apical
chamber, given by the ratio of the fitted k2T(0) for each substrate and the center of the
box value of T (0) = 2x10−4 M. See text and footnote (b) above.
e Center of the box estimate for the dissociation rate constant kr, from P-gp back into the
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inner apical monolayer.
f Equilibrium substrate partition coefficient to 0.1 µm PS/PE/chol (1:1:1) liposomes.
This lipid composition is a rough mimic for the inner apical monolayer, as described in
(24).
g The binding constant to P-gp from the inner apical monolayer, defined by KC = k1/kr.
Below each binding constant, we show in parentheses the appropriate dissociation constant
for each substrate relative to the aqueous cytosol, calculated as KD,Aq =1/(KC*drug par-
tition coefficient{PS/PE/chol}). These are dissociation constants are more than an order
of magnitude smaller than the KM derived from a steady-state Michaelis-Menten analysis
of this data (31).
h Steady state passive permeability coefficients measured across the confluent cell mono-
layer, in the presence of the P-gp inhibitor GF120918, as shown in Figure 3 for quinidine
after 1 hour. PBA is shown first and PAB is shown underneath. The values are not always
symmetric, since the passive permeability for loperamide is faster in the A>B direction
than in the B>A direction before their convergence at steady state. This was also observed
in (23).
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Figure Legends
Figure 1. Model of a confluent cell monolayer, with the apical membrane on top and
the basolateral membrane on the bottom, where it binds to the polycarbonate insert.
Passive permeability occurs in both directions. P-gp expressed on the apical membrane
transports substrate from the inner apical membrane monolayer into the apical chamber.
The concentration of substrate in the apical and basolateral chambers, CA and CB, are
measured, while the concentration of substrate in the inner plasma membrane, CPC , and
the cytosol, CC , are predicted as part of the data fitting process described in Tran et al.
(24).
Figure 2. The total and passive transport of amprenavir into the receiver chamber
across the monolayer of confluent MDCK cells is shown with increasing concentrations of
the quinidine as the inhibitor. Transport is measured by the nmol of amprenavir trans-
ported over time, when the donor side begins with 100 µM amprenavir. The dotted lines
show the nmol transported due to passive permeability (+GF120918) A:B>A, that is, to
the apical chamber from the basolateral chamber marked with solid squares and B:A>B,
that is, to the basolateral chamber from the apical chamber marked by solid triangles. The
two curves are nearly indistinguishable, which is expected for symmetric passive transport.
Error bars are smaller than the symbols. The total transport, P-gp mediated and pas-
sive, A:B>A is shown above the passive permeability lines as a function of the quinidine
concentration (µM), which is inhibiting P-gp via its own transport and, thus, reducing
the amprenevir transport. The total transport B:A>B is shown below the passive per-
meability lines as a function of the quinidine concentration (µM). Here the inhibition of
P-gp by quinidine increases the transport of amprenavir from the apical chamber. At 10
µM quinidine, the amprenavir transport is nearly the same as pure passive permeability.
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Error bars show standard deviation of triplicates. Quinidine at the concentrations shown
is preincubated with the cell monolayer for 0.5 hour and then chamber solutions are re-
placed with 100µM amprenavir in the donor chamber and fresh quinidine solution in both
chambers.
Figure 3. The passive permeability coefficient (+GF120918) for quinidine (QND) over 4
hours in the presence of amprenavir or loperamide is shown with their respective standard
deviations at each time point for all the grouped data sets. All the quinidine data, B>A
and A>B, from 0.1-5µM quinidine, inhibited by either 0-100µM amprenavir (AMP) or
0-10 µM loperamide (LPM) have been included, with a total of 34 data sets. Passive
permeability does not depend upon concentrations of substrate or inhibitor. After 2 hrs,
there is more variability, due in part to the system approaching steady state where the
equation used to calculate the passive permeability coefficient becoming undefined (23).
For fitting P-gp mediated transport of quinidine, the time dependent values of the passive
permeability coefficient up to 1 hr and then the average steady state value calculated for
1.5 hr and beyond is shown by the arrow at about 500 nm/s. For the other substrates, the
crossover time from using the time dependent passive permeability coefficients to using the
steady state average values was chosen the same way. Loperamide’s passive permeability
coefficient in the A>B direction increased to roughly 550 nm/sec at 2 hours and then
declined steadily to roughly 400 nm/sec, so all of the time dependent passive permeability
coefficients were used.
Figure 4. The distribution of the best fitting pairs of the density of eﬄux active P-
gp, T(0), and the association rate constant, k1, for amprenavir alone are shown, following
the fitting algorithm explained in (24). The amprenavir concentrations are color-coded
(black-10µM, red -30µM and blue-100µM). The pairs of {T(0), k1} randomly distributed
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within the box, which looks like a tilted trapezoid shown in blue, give essentially identical
best fits to the data for all these substrate concentrations. The arrows point to parameter
values at the “center of the box”. Table 2 shows these values, i.e. k1 = 2x109M−1s−1
and T(0)=200µM in the inner apical monolayer, which equals 160 P-gp/µm2 in the apical
membrane, see footnote b of Table 2.
Figure 5. The data and fits for the P-gp mediated transport of quinidine with amprenavir
as the inhibitor. All four transport curves are shown here and in the same way in Figures
5-7. For all figures, red denoted concentrations from the apical chamber and blue denotes
concentrations from the basolateral chamber. All data symbols are open, since P-gp is
active in all cases shown, with squares for B>A data and triangles for A>B data, as used
above. Simulations use the parameters given in Table 2, either with the assumption that
the substrate and inhibitor are competing for the “single” P-gp binding site (solid line) or
the assumption that there is no inhibitor effect (dashed line). Since it is very important
to identify which simulation best fits the data, we have made the simulations have thick
lines for the B>A direction and thin lines for the A>B direction. From top to bottom the
curves are denoted: A:B>A, open red squares (), for the concentration of substrate in
the apical chamber when the basolateral chamber is the donor; B:B>A, open blue squares
(), for the concentration of substrate in the basolateral chamber, blue, when the baso-
lateral chamber is the donor; A:A>B, open red triangles (4), for the concentration of
substrate in the apical chamber when the apical chamber is the donor; and B:A>B, open
blue triangles (4), for the concentration of substrate in the basolateral chamber when
the apical chamber is the donor. Data is shown by the symbols with error bars defined
by the standard deviation of triplicate measurements. Fig. 5A shows 0.3µM quinidine
transport in the presence of 100µM of amprenavir as the inhibitor. Competitive inhibition
fits the data very well, while no-inhibitor effect does not. Fig. 5B shows 0.3µM quinidine
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transport in the presence of 50µM of amprenavir as the inhibitor. No inhibitor effect fits
the data very well, as if there is no amprenavir in the system, while competitive inhibition
does not. There is substantial transport of AMP under these conditions, see Figure 6
below. Fig. 5C shows 3µM quinidine transport in the presence of 50µM of amprenavir
as the inhibitor. Competitive inhibition fits the data very well, while no-inhibitor effect
does not. As explained in the text, many other cases were tested and the cases shown in
the figures were chosen to show the substrate and inhibitor concentrations marking the
transition between no-inhibitor effect and competitive inhibition.
Figure 6 shows the data and simulations for the P-gp mediated transport of amprenavir
with quinidine as the inhibitor, using the same nomenclature as Figure 5. Fig. 6A shows
50µM amprenavir transport in the presence of 2µM of quinidine as the inhibitor. No
inhibitor effect fits the data very well, as if there is no quinidine in the system, while
competitive inhibition does not. There is substantial transport of quinidine under these
conditions, see Figure 5 above. Fig. 6B shows 50µM amprenavir transport in the presence
of 5µM of quinidine as the inhibitor. Competitive inhibition fits the data very well, while
no-inhibitor effect does not.
Figure 7 shows the data and simulations for the P-gp mediated transport of quinidine
with loperamide as the inhibitor, using the same nomenclature as Figure 5. Fig. 7A
shows 1µM quinidine transport in the presence of 2µM of loperamide as the inhibitor. No
inhibitor effect fits the data very well. Fig. 7B shows 3µM quinidine transport in the
presence of 10µM of loperamide as the inhibitor. Competitive inhibition fits the data very
well, while no-inhibitor effect does not.
Figure 8. A representation of microvilli on the apical surface of MDCK II cells with
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P-gp expressed on the membrane by arrows. A cartoon path is shown of a random walk
of a substrate molecule after being released either by P-gp or by passive permeability at
the base of a microvillus. The path will involve many subsequent interactions with the
same or a neighboring microvillus. Only substrates released at the tip of the microvilli will
have a reasonable chance of diffusing non-stop into the apical chamber and be counted as
due to transport mediated by eﬄux active P-gp or via passive permeability. Any change
in microvilli dimension would affect the probability of escape non-stop and, hence, the
number of eﬄux active P-gp and the membrane area for passive permeability.
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Figure 9.3: Paper 1: Figure 1 - Model of a confluent cell monolayer
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Figure 9.4: Paper 1: Figure 2 - Inhibition of amprenavir transport by quinidine.
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Figure 9.5: Paper 1: Figure 3 - Passive permeability is time-dependent.
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Figure 9.6: Paper 1: Figure 4 - Best fit values for eﬄux-active P-gp density and the rate
of association to it.
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Figure 9.7: Paper 1: Figure 5a - Quinidine transport inhibited by amprenavir : Compet-
itive inhibition at high inhibitor concentrations.
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Figure 9.8: Paper 1: Figure 5b - No inhibitor effect provides kinetic evidence for atleast
two eﬄux pathways through P-gp.
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Figure 9.9: Paper 1: Figure 5c - Quinidine transport inhibited by amprenavir : competitive
inhibition at high substrate concentrations.
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Figure 9.10: Paper 1: Figure 6a - Amprenavir transport inhibited by quinidine : no
inhibitor effect.
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Figure 9.11: Paper 1: Figure 6b - Amprenavir transport inhibited by quinidine : compet-
itive inhibition at high inhibitor concentrations.
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Figure 9.12: Paper 1: Figure 7a - Quinidine transport inhibited by loperamide : no
inhibitor effect.
114
Figure 9.13: Paper 1: Figure 7b - Quinidine transport inhibited by loperamide : compet-
itive inhibition at high inhibitor concentrations.
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Figure 9.14: Paper 1: Figure 8 - Microvilli morphology plays an important role in the
physiological activity of P-gp.
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10. Paper 2
Kinetic identification of membrane transporters that assist P-gp mediated transcel-
lular transport of drugs through a confluent monolayer of MDCKII-hMDR1 cells.
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Abstract
Identifying the membrane transporters that move substrates across cells is important for
understanding drug absorption / elimination and cell physiology. While the list of mem-
brane transporters involved in intestinal, renal and hepatobiliary transport is extensive,
identification of individual transporters responsible for the transport of substrates across
the basolateral and apical membranes has been challenging. Using a confluent monolayer
of hMDR1-MDCKII cells, the elementary rate constants for the P-gp eﬄux of digoxin,
loperamide, amprenavir and quinidine have been determined. To fit the kinetics of P-gp
eﬄux for digoxin and loperamide, a basolateral transporter has to be introduced into the
kinetic model. Our results show that when a compound is tested against digoxin as a
probe substrate and shown to inhibit B>A digoxin flux, it could be that the inhibition
occurs at the basolateral transporter, rather than at P-gp. Further, digoxin eﬄux requires
an additional apical importer. These putative digoxin and loperamide transporters are
completely inhibited by GF120918, a known P-gp and BCRP inhibitor. In contrast to
digoxin and loperamide, the P-gp substrates amprenavir and quinidine show no kinetic
requirement for these putative transporters. Attempts to identify the additional digoxin
and loperamide transporters using specific substrates for a wide range of known kidney ep-
ithelial transporters (OCT, OAT, OATP, URAT or MRP) failed to elucidate the identity
of these two membrane transporters.
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Introduction
The importance of membrane transporters on the metabolism and disposition of drugs
is well recognized (Goh et al., 2002; Kim, 2003; Mizuno et al., 2003; Collett et al., 2005;
Shitara et al., 2006; Robertson and Rankin, 2006; Sekine et al., 2006). While it is generally
believed that membranes transporters mediate the transcellular transport of compounds
across the epithelial cells of the colon, kidney and liver, and across the endothelial cells
of the blood brain barrier, it has proven very difficult to identify which transporters are
involved in vivo (Lau et al., 2006). The role of additional non-MDR1 transporters medi-
ating the eﬄux of digoxin in Caco-2 cells (Lowes et al., 2003) and influx of mitoxantrone
( a prototype substrate for ABCG2 or bcrp1) in MDCK II cells (Pan and Elmquist, 2007)
have been evidenced. Polarized confluent cell monolayers have be extensively used as
a model to study drug transporters (Tang et al., 2002 a,b; Troutman & Thakker, 2003
a,b; Rautio et al., 2006). There has been success in transfecting these model systems
with exogenous transporters to study their interactions (Sasaki et al., 2004; Spears et al.,
2005). However, the problem is that the interactions are complex and the analysis has
been limited to known transporters (Dresser et al., 2001; Shitara et al., 2006).
We have developed a kinetic analysis that can detect the presence of unknown trans-
porters and can assay their inhibition with great sensitivity. Using the polarized MDCKII-
hMDR1 confluent cell monolayer, which overexpresses P-gp in the apical plasma mem-
brane, and a detailed mass action kinetic analysis of P-gp eﬄux, we have been able to
answer several fundamental questions about P-gp function (Tran et al., 2005; Bentz et al,
2005; Acharya et al. 2006). The basic experimental design was to measure the total trans-
port (e.g., P-gp and passive permeability) and passive permeability of substrates through
the cell monolayer. The difference in these two rates theoretically provides the kinetics of
P-gp transport alone.
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The objective of this work was to 1) demonstrate the kinetic importance of unknown
membrane transporters in the transport of the P-gp substrates loperamide and digoxin
across the basolateral and apical membranes of MDCK-hMDR1 monolayers, 2) attempt
to identify these unknown transporters using a wide range of transporter substrates and
inhibitors.
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Materials and Methods
Materials. Amprenavir and GF120918 were from GlaxoSmithKline (USA), loperamide
was from Sigma, and quinidine was from Fisher Scientific. 3H-loperamide (10 Ci/mmole)
and 3H-amprenavir (21 Ci/mmole) were custom synthesized by Amersham Pharmacia
Biotech, England. 3H-quinidine (20 Ci/mmole) was from ICN Biomedical, Inc. USA.
Dulbecco’s Modified Eagle Medium (DMEM) was from MediaTech, VWR. DMEM with
25 mM HEPES buffer, high glucose (4.5 g/L), L-Glutamine, pyridoxine hydrochloride,
w/o sodium pyruvate, and with phenol red was from Gibco. The same medium with-
out phenol red was used for transport experiments, denoted transport media. Transwell
12-well plates with polycarbonate inserts (0.4µm pore size and 12 mm diameter) were
obtained from Costar (Acton, MA). All compounds tested in Table 2 were from Sigma
(Sigma Chemical Co., St.Louis, MO).
Cell line and culture conditions. The Madin-Darby Canine Kidney II cell line
which over-expresses human MDR1 (MDCKII-hMDR1) was purchased from the Nether-
lands Cancer Institute (Amsterdam, Netherlands) (Evers et al., 2000). MDCK II cells
were grown in 175 cm2 culture flasks using DMEM with 10% fetal bovine serum, 1%
L-glutamine and 50 U/mL penicillin, 50 mg/mL streptomycin at 37◦C in 5% CO2 atmo-
sphere. Cells were split twice a week at 70-80% confluency in a ratio of 1:40, after at least
2 washes in PBS and being trypsinized with 0.25% trypsin/EDTA. All transport assays
were done with cells from passages 30 to 55. Cells were kept at 37◦C in 5% CO2.
Single substrate eﬄux assay. Cells were seeded in 12 well Costar-Transwell plates
with polycarbonate membrane inserts at a density of 175,000 cells per insert and grown for
four days in culture medium. Cells were given fresh media 1 day after seeding. On the day
of the experiment, culture media was removed and cells were pre-incubated for 30 minutes
with either transport media alone or transport media with 2 µM GF120918, an inhibitor
121
of P-gp and BCRP. Eﬄux of a range of substrates across the confluent monolayer of cells
was measured in both directions, i.e. apical to basolateral (A>B) and basolateral to apical
(B>A) in the presence and absence of GF120918. 3H-amprenavir, 3H-quinidine, or 3H-
loperamide (0.5 mCi/mL) was added to each respective substrate concentration to allow
quantitation of eﬄux from donor to receiver chambers. Lucifer yellow (100µM) was added
to the donor chamber to monitor integrity of confluent cell monolayer. Samples (25 µL)
were taken over a period of 4 or 6 hours, as shown, from both donor and receiver chambers
into 96-well Lumaplates, dried overnight and the radioactivity counted by TopCount Model
9912 (Perkin Elmer, USA ). The initial concentration measurement was taken at 6 min
after the addition of substrate in the first well (Tran et al., 2004, 2005) and subsequent
measurements taken at multiple time points up to 6 hours for all experiments (Tran et al.,
2005). After taking each aliquot, the Transwell plates were replaced in a shaker at a speed
of 30 rpm, at 37◦C in 5% CO2 . Fluorescence of lucifer yellow (Ex max = 438nm, Em
max = 530nm) was measured at time zero from aliquots taken directly from the vials and
compared to samples aliquoted at the end of the experiment from both the basolateral
and apical chambers; the fluorescence was analyzed using a SpectraMax microplate reader.
Passive permeability of Lucifer yellow was always <10 nm/s over the experiment.
Inhibition studies. Cells were seeded and fed as described above and on the day of
the experiment culture medium was removed by aspiration. The cells were then prein-
cubated with the inhibitor/substrate drug in both chambers for 30 min. During the
preincubation, half the wells received inhibitor solution without GF120918 (to study ac-
tive transport) and the other half received inhibitor solution with GF120918 (to study
passive transport). After 30 minutes, the preincubation solutions were removed by as-
piration and the labeled substrate was added to the donor chamber, while refilling fresh
inhibitor solution in both chambers, again one half without GF120918 and the other half
with it.
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Digoxin cell concentration exclusion assay. Cells were seeded and fed as de-
scribed above. On the day of the experiment, culture medium was removed by aspiration.
The cells were then pre-incubated for 30 minutes with transport media (TM), TM +
quinidine (20µM), TM + GF120918 (2µM), TM + quinidine (20µM) +GF120918 (2µM)
in both chambers. All these pre-incubation conditions were in triplicates. Pre-incubation
solutions were then removed by aspiration. Donor and receiver solutions contain the radi-
olabeled substrate digoxin (50µM) in addition to the respective preincubation condition.
Basolateral and apical chambers were filled with donor and receiver solutions respectively.
Transport from B>A was measured over 4 hours. Since the same concentration of digoxin
was used on both sides, a flat curve showing steady state was obtained. At the 4th hour,
all solutions were removed. Both chambers were washed 3 times with cold transport me-
dia containing 2µM GF120918. The polycarbonate membrane inserts with the cells were
carefully cut out and radioactivity associated to the cells on the membrane was counted
by liquid scintillation. The same protocol was repeated using 1µM benzbromarone in
addition to quinidine.
Cell stability and substrate metabolism. We showed previously that the stability
of the cell monolayer and plasma membrane with respect to passive and active transport
was not affected by the prolonged exposure times to amprenavir for at least 6 hr (data
not shown; Tran et al., 2005). It was also shown that metabolism or decomposition was
insignificant for amprenavir, quinidine and loperamide on this time scale using radio-HPLC
(data not shown; Tran et al., 2005).
Numerical integrations. We used the stiffest integrator in MATLAB, ode23s, with
absolute and relative tolerances set to 10−8. Other MATLAB integrators, while faster,
were not accurate enough at the later times of simulations. In data fitting, all concentra-
tion curves are simultaneously fitted, so that despite the fact that the A:B>A curve, i.e.
substrate concentration in the apical chamber when the basolateral chamber is the donor,
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is the most visually striking, all curves contribute to minimizing the difference between
data and simulated curves. MATLAB fminsearch minimizes the coefficient of variation
between the data and the simulated curves. Further details can be found in Tran et al.
(2005) and Bentz et al. (2005).
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Mass Action Kinetic Model
Figure 1 is a cartoon of a confluent cell monolayer, featuring the polarized MDCKII-
hMDR1 cells, where the basolateral membrane is attached to the polycarbonate filters and
P-gp (upward arrows) expressed on the apical surface. The apical and basolateral cham-
bers are kept separate by the tight junctions. Active transport by P-gp occurs vectorially,
with substrate binding to a site on P-gp within the apical membrane inner monolayer and
with eﬄux into the apical chamber (Loo and Clarke, 2005; Lugo and Sharom, 2005). For
many substrates, including those studied here, passive permeability is a significant frac-
tion of total transport and is quantitatively analyzed separately using the P-gp inhibitor,
GF120918 (Tran et al., 2004, 2005; Acharya et al., 2006).
With the confluent cell monolayer system, we measure the concentration of substrate in
the apical chamber, denoted CA, and the basolateral chamber, denoted CB. However, the
concentration of substrate in the cytosol, denoted CC , and in the inner plasma membrane
in contact with the P-gp binding site, denoted CPC , cannot be measured rigorously in
real time. These internal concentrations are variables of the mass action model and fitted
by elementary rate constants for well-defined kinetic barriers, according to the measured
values of CB and CA over time (Tran et al., 2005; Acharya et al., 2006).
The simplest Michaelis-Menten mass action reaction to model P-gp is:
T0 + Cpc
k1

kr
T1
k2−→ T0 + CA (10.1)
where T0 is the empty transporter, CPC the substrate in the apical membrane inner
monolayer, T1 is the transporter bound by substrate and CA the substrate after eﬄux
into the apical chamber. Although P-gp has more than one eﬄux binding site, when the
inhibitor concentrations are near the IC50, P-gp behaves like a simple single competi-
125
tive site transporter (Acharya et al., 2006). The additional transporters are modeled by
Michaelis-Menten steady-state equations
dC
dt
(Transporter) =
Vmax[C]
KM + [C]
KM>>[CPC ]−→ Vmax
KM
[C] (10.2)
This was a compromise between rigor and flexibility, since this model can roughly
assess whether there is a kinetically significant binding step with the transporter prior to
influx into the cell, without having to fit real binding constants, as done previously for P-
gp. For each transporter, both Vmax and KM are used to fit the data, but we have found,
thus far, that only the ratio Vmax/KM (s−1) was constant. From Eq. (3), this would
imply that the KM of the transporter is much larger than the substrate concentration
in the inner apical membrane. For this modeling, we have assumed that the unknown
transporters are facilitated transporters, i.e. they support transport in both directions.
This was not a strong assumption, since substrate flux was mostly unidirectional during
these experiments. Once the transporters are identified, more rigorous modeling can be
applied.
The cells do not lose any capacity for drug transport over 6 hour incubations (Tran
et al., 2005; Acharya et al., 2006), implying that cellular ATP levels remain adequate for
full P-gp function throughout experiment. The passive permeability coefficients used in
the mass action model were determined in the presence of 2 µM of the GF120918 (Hyafil
et al., 1993; Polli et al., 2001; Tran et al., 2004, 2005).
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Results
Loperamide transport requires an additional basolateral transporter. The ki-
netic parameters for P-gp transport published in Acharya et al. (2006), and shown in
part here in Table 1, assumed that P-gp was the sole transporter. This model works very
well for amprenavir and quinidine. The transport of loperamide (10µM) in the apical-to-
basolateral (A>B) and basolateral-to-apical (B>A) directions across MDCKII-hMDR1
monolayers is shown in Figure 2 and the model, shown by the lines through the data
points, fits the experimental data reasonably well.
However, as shown originally in Tran et al. (2005) and confirmed in Acharya et al.
(2006), the “P-gp alone” model gave adequate fits for loperamide only with concentra-
tions above 3µM. At lower concentrations, more loperamide transport was observed than
could be fitted assuming only passive permeability (i.e. +GF120918) and P-gp mediated
transport. The passive permeability coefficients calculated in the presence of GF120918
were too small to account for the measured eﬄux, even when the P-gp parameters were
set to maximal values.
This is shown in Figure 3 by the dotted lines, which substantially underestimate the
flux of 1µM loperamide shown by the data points. Addition of a basolateral transporter
with V max/KM = 100s−1 yields a much better fit to the experimental data (Table 1
and Figures 3, solid lines). Both Vmax and KM were fitted separately, but only their
ratio was constant suggesting that a single transporter is responsible for the increased
flux. This kinetic evidence highlights the significant contribution of an uptake basolateral
transporter for loperamide at lower concentrations.
After about 4 hours, the fit slightly overestimates the apical concentration. If there
were an apical transporter for loperamide, in addition to P-gp, then the final steady state
concentration for loperamide in the apical chamber would be smaller. Indeed, a better
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fit at 4 hrs can be found with the addition of this second eﬄux transporter (not shown).
However, the deviation is likely experimental error as the parameters in Table 1 support
the need for only a basolateral transporter. The effect of a second apical eﬄux transporter
should be more pronounced for even lower loperamide concentrations. As expected the
difference between the dotted line and the data points is larger for 0.03µM loperamide
(Figure 4). But an additional apical transporter is not required to fit loperamide transport
at 0.03 µM (fit not shown).
Digoxin is transported by both a basolateral and an apical transporter.
We measured digoxin transport across the MDCKII-MDR1 cell monolayers for 6 hours
starting with 1µM digoxin in the basolateral chamber. The flux of digoxin into the apical
chamber is linear with time, yielding no “fittable” data, as some degree of saturation is
required to derive values for the kinetic parameters. When the cells were incubated for
an extended the time (>6 hrs), the transport curves showed a clear toxic effect (data not
shown).
This led us to construct a “data stitching” method to measure transport over longer
time periods. Once the concentrations of digoxin in the apical and basolateral chambers
at the 6th hour are known, the next experiment begins with the initial concentration of
digoxin in both chambers matching those at the 6th hour. Using this approach, data is
collected for consecutive stretches of 6 hours and stitched together to create a time course
curve up to 30 hours (Figure 6). The only artifact in stitching is that the cytosol is initially
empty of substrate. However, as the volume of the confluent cell monolayer cytosol is very
small, steady state will be reached within the first few minutes of substrate addition (Tran
et al., 2004; Acharya et al., 2006).
The kinetic fits for the digoxin concentration time curve are shown in Figure 7. The
dotted line shows the fit using just the “P-gp alone” model, which underestimates trans-
port by approximately 50%. The solid line shows the fit using a basolateral transporter
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with V max/KM = 30s−1 and the parameters given in Table 1. Both Vmax and KM
were fitted separately, but only their ratio was constant, which suggests that only one
transporter is responsible. The solid line fits well up to 12 hours. However, beyond
12 hrs, it predicts too much transport. Addition of a second apical transporter with a
V max/KM = 2s−1 for digoxin, in addition to P-gp and the basolateral transporter, yields
a lower final steady state concentration for digoxin in the apical chamber (Figure 7, dashed
line). The contribution of the apical transporter is more than experimental error, unlike
the case for loperamide (Figure3).
In order to determine the identity of these transporters involved with digoxin transport,
inhibition studies were completed with a variety of prototypical substrates or inhibitors for
OAT, OCT and MRP transporters (Table 2). The compounds mentioned in Table 2 were
selected for inhibition studies because they cover a broad range of possibilities for known
transporters on the basolateral and apical membranes of kidney cells. The concentrations
of the compounds were chosen based on their KI or IC50 values reported in the papers
cited. To evaluate whether these compounds have any effect on loperamide or digoxin
transport, we used concentrations higher than the maximum concentration used for the
experiments in the respective papers. This was a reasonable starting point because high
concentrations would ensure that any effect on the transport of the probe substrates did
not go undetected.
By incubating cells with a high concentration of a substrate or an inhibitor for the
basolateral transporter, the transport of digoxin should decrease to the levels predicted by
the P-gp eﬄux alone curves (i.e. a 50% reduction in transport). This makes the kinetic
analysis a very sensitive instrument for determining the identity of the basolateral trans-
porter. Except for loperamide, incubations with the prototypical substrates/inhibitors
failed to inhibit digoxin transport suggesting these candidate transporters were not the
unknown basolateral transporter involved in flux of digoxin across the MDCKII-hMDR1
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cell line. The inhibition of digoxin transport by loperamide, and vice versa, certainly in-
volves P-gp, but we further studies are required to determine whether they share a single
basolateral transporter, or whether there are two different basolateral transporters.
Out of all the substrates/inhibitors tested, only 100µM and 200µM benzbromarone
inhibited 1µM digoxin transport in the B>A direction by 20% and 50% respectively (data
not shown), but these concentrations also showed toxic effects on the cells, i.e. the trans-
port curves stopped abruptly after a few hours and the cell monolayer became leaky. These
results led us to perform the cell concentration exclusion assay using 1µM benzbromarone
with the aim to find out if it actually caused less accumulation of digoxin in the cells.
Cell concentration exclusion assay shows benzbromarone selectively in-
hibits digoxin accumulation within the cell monolayer. The amount of radioac-
tivity from digoxin associated to the cells was measured in the presence and absence
of benzbromarone. Presumably if Benzbromarone inhibits the basolateral and/or apical
transporter/s, then less digoxin would be accumulated within the cells. Figure 8 shows
cellular digoxin radioactivity by itself, and in the presence of quinidine (a P-gp substrate-
inhibitor), GF120918 (inhibits P-gp and the additional basolateral and apical transporters)
and benzbromarone. Digoxin, quinidine, benzbromarone and GF120918 are abbreviated
as DGX, QND, BZB and 918 respectively. In presence of 20µM quinidine, P-gp is rela-
tively saturated with quinidine (Acharya et al., 2006) and there is more digoxin present
within the cells compared to digoxin alone. In presence of 2µM GF120918 , P-gp and
the additional transporters are completely inactive and there is even more digoxin present
within the cells. In contrast, in presence of 1µM benzbromarone there is significantly less
digoxin accumulation, suggesting inhibition of a basolateral and/or apical uptake trans-
porter/s. This led us to investigate the effect of 1µM benzbromarone on digoxin transport
(figures 9 and 10) . With 1µM benzbromarone the monolayer was tight up to 4 hours,
i.e. the total flux of lucifer yellow remained < 10nm/s. Therefore 1µM benzbromarone
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doesn’t have toxic effects on cells.
There is no effect of 1µM benzbromarone on the B>A or A>B transport of
1µM digoxin. To investigate if benzbromarone has any effect on digoxin transport due to
its possible interaction with the additional basolateral or apical transporter, a bidirectional
digoxin transport curve was generated in the presence and absence of benzbromarone.
Figure 9A and 9B shows nmoles of digoxin transported B>A and A>B over 6 hours with
a starting concentration of 1µM digoxin in the donor side in presence and absence of 1µM
benzbromarone. There is no significant effect (p 0.05 for both B>A and A>B directions
based on linear regression analysis) of 1µM benzbromarone on digoxin transport.
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Discussion
The rigorous kinetic analysis of P-gp mediated transport through the confluent MDCKII-
hMDR1 cell monolayer has provided a quantitative view of P-gp function through the
elementary rate constants (Tran et al., 2005; Acharya et al., 2006). The kinetic modeling
work presented here provides evidence for other unknown transporter(s) in the MDCKII
cells which facilitate the passage of loperamide and digoxin through the basolateral mem-
brane, so that they can reach P-gp more quickly than by simple passive permeability.
In addition, there appears to be an apical transporter that allows digoxin re-entry into
the cells after eﬄux into the apical chamber. Each of these transporters is inhibited by
GF120918. These findings have expanded the kinetic modeling from its focus on P-gp
mechanism to a tool to elucidate other transporters involved in transcellular transport.
The current fitted parameters for P-gp shown in Table 1. The transcytosis of ampre-
navir and quinidine across the MDCKII-hMDR1 confluent cell monolayer are quantita-
tively fitted by P-gp and passive permeability alone. In Tran et al. (2005) and Acharya
et al. (2006), it was noted that for loperamide there was another process affecting the
B>A transport. By adding a facilitated transporter to the basolateral membrane allows
the loperamide data from 12nM to 30µM to be fitted with the parameter values shown in
Table 1. At and above 30µM loperamide, P-gp is completely saturated and contributes
little to the total transport relative to passive permeability alone. This addition to the
kinetic model for loperamide has changed the estimate for loperamide’s binding constant
from 4,000 M−1 (Acharya et al., 2006) to 20,000 M−1 (Table 1). The reason for this
increase is that the binding constant, KC , is primarily fitted by the A>B transport (Tran
et al., 2005) and the basolateral transporter for loperamide speeds up permeation to the
basolateral chamber. Thus, a stronger binding constant to P-gp is required to fit the same
A>B flux data.
132
The flux of loperamide from the basolateral chamber into the cytosol is 60% due to
passive permeability (+GF120918) and 40% due to this transporter (-GF120918) (Table
1). This transporter could be active, directed from basolateral to cytosol, but future
studies will be required to clarify this point, including finding some compound to inhibit
the transporter.
For digoxin, using the stitched data to approximate a 30 hour transport experiment,
both a basolateral transporter and an apical transporter are needed to fit the experimental
data. The passive flux of digoxin from the basolateral chamber into the cytosol is 30%
due to passive permeability (+GF120918) and 70% due to this basolateral transporter.
Conversely, from the apical chamber into the cytosol, the flux is 95% due to passive per-
meability (+GF120918) and 5% due to the apical transporter (-GF120918). In contrast
to digoxin and loperamide, neither amprenavir nor quinidine showed any significant im-
provement in fit with additional transporters aside from P-gp, suggesting that any other
transporter has a kinetically insignificant rate.
We have tried to identify these transporters by adding prototypical substrates of known
transporters and determining whether the loperamide or digoxin transport curves would
drop to the levels predicted by the “P-gp only” curves (Figures 3, 4 and 7). The change
in the predicted curves would be very large, making the kinetic modeling an extremely
sensitive assay for discovering functional transporters in the confluent cell monolayer.
None of the compounds tested in Table 2 affected transport during the first few hours.
There were some changes noted after 2-3 hours, but these appeared to be due to toxicity.
A cell concentration exclusion assay was also tried, wherein the concentration of digoxin
within the confluent cell monolayer was assayed as a function of benzbromarone concentra-
tion, as influx of digoxin into the cytosol is mainly due to transporters. It was anticipated
that in the presence of an inhibitor, there should be a large reduction in accumulated
digoxin. Addition of benzbromarone resulted in a very significant reduction of digoxin ac-
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cumulation within the cell monolayer. However, benzbromarone had no significant effect
on digoxin B>A or A>B transport in the same cellular system. Thus, the reduction in cell
associated digoxin by benzbromarone is due another mechanism besides the unknown “ki-
netic” basolateral or apical transporter. The simplest hypothesis is that benzbromarone
reduces the cell’s cytosolic volume, so less digoxin can accumulate. This would have no
predicted change in transport of digoxin, since the kinetic model predicts that most of
it diffuses along the inner plasma membrane. Transcellular transport of amphipathic P-
gp substrates depends upon plasma membrane area, not on cell volume. This suggests
that cell concentration exclusion assays must be carefully controlled when used with am-
phiphilic compounds eﬄuxed from transporter whose binding sites are within the plasma
membrane, like P-gp or the MRPs (Lugo & Sharom, 2005; Borst et al., 2005).
These results lead us conclude that digoxin and loperamide are not good candidates
for a probe substrate with the MDCKII-hMDR1 cell line. If a drug inhibits B>A digoxin
flux, it could be that the inhibition occurs at the digoxin basolateral transporter, rather
than at P-gp. On the other hand, it appears that quinidine or amprenavir are safe probe
substrates for this cell line, since their B>A transport could be inhibited only at P-gp.
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Figures
Figure 10.1: Paper 2: Table 1 - Fitted Parameter Values with Single Substrate Experi-
ments
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Legend for Table 1.
a Estimate for the eﬄux rate constant k2, from P-gp into the apical chamber, given by the
ratio of the fitted k2T(0) for each drug and the center of the box value of T (0) = 2x10−4 M.
b Estimate for the dissociation rate constant kr, from P-gp back into the inner apical
monolayer.
c The binding constant between P-gp and the inner apical monolayer shown is the av-
erage of the best fits (> 160 for each drug concentration). Below each binding constant,
we show in parentheses the appropriate dissociation constant for each drug relative to the
aqueous phase, calculated as KI,Aq =1/(KC*drug partition coefficient{PS/PE/chol}), the
liposome mimic for the inner apical monolayer. These aqueous dissociation constants are
given only to a single significant digit and no error bars were calculated.
d Equilibrium drug partition coefficient to 0.1 µm PS/PE/chol (1:1:1) liposomes. This
lipid composition is a rough mimic for the inner apical monolayer, as described in Tran et
al. (2005).
e Steady state passive permeability coefficients measured across the confluent cell mono-
layer, in the presence of the P-gp inhibitor GF120918. PBA is shown above and PAB
is shown beneath. The values are not always symmetric, since the passive permeability
for loperamide is faster in the A>B direction than in the B>A direction. This was also
observed in Tran et al. (2004).
f The fits for the basolateral transporter, where both Vmax and KM were free, but
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only their ratio was constant. Amprenavir and quinidine were completely fitted by P-gp
and GF120918 passive permeabilities. This does not mean they cannot use the basolateral
transporter, just that little if any of their transport is due to the basolateral transporter.
The same is true for the apical transporter, with the addition that loperamide shows no
significant transport through it. % GF120918 transport is the fraction of transport into
the cytosol, B>C or A>C, due to the transporter, relative to all +GF120918 passive
transport.
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Figure 10.2: Paper 2: Table 2 - List of compounds tested to identify additional transporters
for loperamide and digoxin.
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Legend for Table 2.
a The compounds used here are substrates and/or inhibitors of known mammalian trans-
porters. Names of all human transporters (OATs, OATPs, MRPs) are in upper case.
Transporters in mice or rats are in all lower case (e.g. oatp) or start with an upper case
letter followed by the rest in lower case (e.g. Oat).
b NA denotes not applicable.
c Best inhibition is seen when there is digoxin transport in presence of ouabain with-
out any preincubation. 30mins preincubation with ouabain produces a jump at 4hrs.
d 100 and 200µM benzbromarone were tested but these concentrations had toxic effects
on cells.
e No effect means lack of significant (>10%) inhibition by 2 hrs.
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Figure Legends
Figure 1. Cartoon model of a confluent cell monolayer. It shows the apical
membrane with microvilli on top and the basolateral membrane on the bottom, where the
cells attach to the polycarbonate insert. Passive permeability occurs in both directions.
This is measured when P-gp is completely inhibited by GF120918. P-gp expressed on
the apical membrane transports substrate from the inner apical monolayer into the apical
chamber. The concentration of substrate in the apical and basolateral chambers, CA and
CB, are measured. The concentration of substrate in the inner plasma membrane, CPC ,
and the cytosol, CC , are predicted as part of the data fitting analysis. Transporters other
than P-gp are known to operate in the basolateral and apical membrane, that might in-
fluence the uptake and eﬄux rates of P-gp substrates.
Figure 2. 10µM Loperamide transport data can be fitted using just P-gp pa-
rameters. This figure shows the concentration of loperamide over time in each chamber
starting with 10µM loperamide initially in the donor chamber across the MDCKII-MDR1
cell monolayer. The B:B>A and A:B>A curves denote the concentration of drug in the ba-
solateral and apical chambers when the basolateral chamber was the donor, i.e. transport
runs B>A. Similarly, the A:A>B and B:A>B curves denote the concentration of drug in
the apical and basolateral chambers when the apical chamber was the donor, i.e. transport
runs A>B. B>A data are shown by open squares () when the apical chamber is sampled
and by open circles (◦) when the basolateral chamber is sampled. Open triangles (4) and
diamonds (3) represent concentrations measured in the apical and basolateral chambers
when transport run from A>B. The fits for the basolateral data are shown by the solid line
(–), i.e. both B:B>A and B:A>B. The fits when the apical chamber is sampled are shown
by the dotted line (...), i.e. both A:B>A and A:A>B. The same symbols and notations
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are used in Figures 3, 4, 5, 6 and 7. All data points represent triplicate measurements at
each time point with the corresponding standard deviation. The fits use the parameters
published in Acharya et al. (2006) for loperamide, which assumed no other transporters
beyond P-gp. There is reasonably good fit to the data as the lines depicting the simula-
tions pass through the data points representing triplicate measurements at each time point.
Figure 3. 1µM loperamide needs a basolateral transporter. This figure shows the
concentration of loperamide over time in each chamber starting with 1µM loperamide
initially in the basolateral donor chamber. The dotted line shows the fit using the
parameters for only P-gp mediated loperamide transport which clearly underestimates
amount of transport. The solid line shows the fit using a basolateral transporter with
Vmax/KM=100s−1. Both Vmax and KM were fitted separately, but only their ratio was
constant.
Figure 4. Loperamide only needs a basolateral transporter. This figure shows the
concentration of loperamide over time in each chamber starting with 0.3µM loperamide
initially in the donor chamber across the MDCKII-MDR1 cell monolayers. The dotted line
shows the fit using the loperamide parameters from Acharya et al. (2006), which clearly
underestimates transport by about 40% which is much more than was seen in figure 3
for 1µM loperamide. The solid line shows the fit in presence of P-gp and a basolateral
transporter with Vmax/KM=100s−1.
Figure 5. Digoxin transport curve is generated by measuring transport over
consecutive stretches of 6 hours. This figure shows the concentration of digoxin over
time in each chamber starting with 1µM initially in the basolateral donor chamber across
the MDCKII-MDR1 cell monolayers. The increase of digoxin concentration in the apical
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chamber is linear, so fitting is not possible. To measure transport for a longer time course,
we adopted a “data stitching” method. Once we know the concentrations of digoxin in
the apical and basolateral chambers at the 6th hour, we start the next experiment such
that the initial concentration of digoxin in both chambers match (as closely as possible)
those at the 6th hour.
Figure 6. Digoxin transport curve is generated by stitching transport data
upto 30 hours. This figure shows the concentration of digoxin over time in each chamber
starting with 1µM initially in the basolateral donor chamber across the MDCKII-MDR1
cell monolayers. The concentration of digoxin in the apical chamber increases over time
and finally reaches a steady state.
Figure 7. Digoxin is transported by a basolateral and an apical transporter,
in addition to P-gp. This figure shows the concentration of Digoxin over time in each
chamber starting with 1µM digoxin initially in the basolateral donor chamber. The dotted
line shows the “best” fit using P-gp parameters, basically set to infinite forward values,
which clearly underestimates transport by about 50%. The solid line shows the fit using
the parameters given in Table 1 of this work, which has a basolateral transporter with
Vmax/KM=30s−1 in addition to P-gp. The solid line fits up to 12 hours and beyond that,
it predicts more transport than we actually measure. If there were an apical transporter
for digoxin, in addition to P-gp, then the final steady state concentration for digoxin in the
apical chamber would be smaller. This is shown by the dashed line, with Vmax/KM=2s−1
for the additional apical transporter.
Figure 8. Digoxin cell concentration exclusion by benzbromarone. This figure
shows radioactivity in disintegrations per minute from radiolabeled digoxin in MDCKII-
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hMDR1 cells by itself (column A) , in presence of quinidine (a P-gp substrate-inhibitor)(column
B), GF120918 a potent inhibitor of P-gp and both the additional digoxin transporters
(column C) and benzbromarone (substrate for MRP1, MRP2, hURAT1) (column D). In
presence of 20µM quinidine (column B), there is more digoxin bound to cells compared to
digoxin alone. There is even more digoxin bound when P-gp and the other transporters are
completely inhibited by GF120918 (column C). The highlight of this figure is the small-
est bar (column D), which shows there is significantly less digoxin bound in presence of
benzbromarone, suggesting that it interacts with the basolateral and/or apical transporter
for digoxin and blocks digoxin entry into the cells. Digoxin, Quinidine and GF120918 are
abbreviated as DGX, QND and 918 to fit them into the figure.
Figure 9. There is no effect of 1µM benzbromarone on the transport of 1µM
digoxin. Figure 9A shows nmoles of digoxin transported B>A over 6 hours when the
donor starts with 1µM digoxin in the presence and absence of 1µM benzbromarone in both
chambers. Circles and triangles represent presence and absence of 1µM benzbromarone
during digoxin transport. Same abbreviations are used as in figure 8. Benzbromarone
is abbreviated as BZB. The circles and triangles are open (◦, 4) when there is active
transport and closed (•,N) when there is GF120918 to inhibit both P-gp and the putative
transporters.
Similarly, in figure 9B , A>B transport of 1µM digoxin in the presence and absence of
1µM benzbromarone is shown. Open squares () represent transport of digoxin alone and
open circles (◦) depict digoxin transport in presence of benzbromarone. The corresponding
filled symbols represent A>B flux in presence of GF120918. Benzbromarone is not a
specific inhibitor for the putative basolateral/apical transporter since it has no effect on
digoxin transport.over a period of 6 hours in either direction.
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Figure 10.3: Paper 2: Figure 1 - Cartoon model of a confluent cell monolayer.
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Figure 10.4: Paper 2: Figure 2 - 10µM Loperamide transport data can be fitted using just
P-gp parameters.
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Figure 10.5: Paper 2: Figure 3 - 1µM loperamide needs a basolateral transporter.
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Figure 10.6: Paper 2: Figure 4 - Loperamide only needs a basolateral transporter.
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Figure 10.7: Paper 2: Figure 5 - Digoxin transport curve generated by measuring transport
over consecutive stretches of 6 hours.
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Figure 10.8: Paper 2: Figure 6 - Digoxin transport curve upto 30 hours.
153
Figure 10.9: Paper 2: Figure 7 - Digoxin is transported by a basolateral and an apical
transporter, in addition to P-gp.
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Figure 10.10: Paper 2: Figure 8 - Digoxin cell concentration exclusion by benzbromarone.
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Figure 10.11: Paper 2: Figure 9 - There is no effect of 1µM benzbromarone on the
transport of 1µM digoxin.
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11. Paper 3
For P-glycoprotein-like mediated transport through a confluent cell monolayer, the
IC50 of a P-gp substrate depends upon the probe substrate kinetic parameters.
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Abstract
Typically, the inhibition of membrane transport is quantified by the IC50, i.e. the con-
centration of inhibitor required to reduce substrate transport by 50%. This analysis was
developed for soluble enzymes and, in the limit of small substrate concentration, the IC50
is equal to the thermodynamic dissociation constant of a competitive inhibitor for the
enzyme. For membrane transporters whose binding site resides in the inner monolayer of
the plasma membrane, like P-gp and MRP, there is a permeability barrier between the
binding site and the extracellular space. For these transporters, there has been no test
of the correlation between the IC50 and the dissociation constant of the inhibitor. Previ-
ously, we have fitted the mass action elementary kinetic rate constants of P-gp transport
of several different drugs through a confluent monolayer of MDCKII-hMDR1 cells. We
found that the IC50 values were an order of magnitude or more larger than the dissocia-
tion constants derived from the elementary rate constants. Here we use these elementary
rate constants to create computer simulations where the transport of probe substrate over
time was calculated as a function of inhibitor concentrations, thus yielding IC50 values.
These simulations prove that the IC50 value can be orders of magnitude larger than the
dissociation constant for the inhibitor. We show that this overestimate is a simple func-
tion of cell and substrate parameters, but is independent of inhibitor parameters. We
follow A>B transport in detail, where the overestimate is shown to be is due to a rapid
steady-state established between the donor chamber and the cytosolic volume, because of
the very small cytosolic volume. This shows that extrapolation of an IC50 value from one
cell line to another or to in vivo will depend upon many factors beyond just the binding
constant of the inhibitor to the transporter. All of the conclusions we reach here hold for
any small volume system, e.g. suspension or plated cells.
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Introduction
The importance of membrane transporters on the metabolism and disposition of drugs
is clear (Goh et al., 2002; Mizuno et al., 2003; Chang and Benet, 2005; Collett et al.,
2005; Shitara et al., 2005; Robertson and Rankin, 2006; Sekine et al., 2006). One typical
experiment in the study of drug-drug interactions is the inhibition of transport of one drug
by another, quantified by the concentration of inhibitor required to reduce drug transport
by 50%, i.e. the IC50. This analysis was developed for water-soluble enzymes which bind
drug, and/or inhibitor, directly from the aqueous phase to which the drug is added ini-
tially. So, it is likely to work for membrane transporters that bind their drug directly from
the water phase, e.g. glucose permeases (Hah et al., 2002). However, for transporters that
bind drug from the inner apical or basolateral monolayer of the cell plasma membrane,
e.g. P-gp (Loo and Clarke, 2005; Lugo and Sharom, 2005) and MRP (Borst et al., 2006),
the binding site is at least one permeability barrier away from the drug. This suggests, at
least, that passive permeability through the plasma membrane may affect the correlation
between the inhibitor’s dissociation constant and it’s IC50.
Using an MDCKII-hMDR1 confluent cell monolayer, we have fitted the elementary
rate constants for substrate binding to and eﬄux from P-gp for amprenavir, quinidine
and loperamide (Tran et al., 2005; Acharya et al., 2006). As expected, each of the P-gp
substrates inhibited the transport of the other P-gp substrates (Acharya et al., 2006).
However, we also found that the IC50’s we measured, as well as those in Rautio et al.
(2005) for the same substrates/inhibitors, were much larger than the fitted dissociation
constants of the inhibitors, even with very low concentrations of substrate. For the con-
fluent cell monolayer, there is a kinetic barrier between the P-gp binding site, within the
inner apical membrane, and the extracellular space where the drugs are initially added.
This suggested that the substrate parameters describing transport through the intervening
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kinetic barrier could be convolved with the IC50, as is the case for the Michaelis constant
KM when the Michaelis-Menten equations are used to analyze P-gp mediated transport
through the confluent cell monolayer (Bentz et al., 2005).
This question cannot be answered by experiments alone, since ambiguities can always
be ascribed to the use of different cell lines or other effects. A more rigorous analysis
of the transport kinetics is required, which starts from the same mass action reactions
as used by the standard IC50 and the Michaelis-Menten analyses. This allows computer
simulations of substrate transport in the presence of “virtual inhibitors”. Following this
approach, we have found that the overestimate of the inhibitor’s dissociation constant by
its IC50 will occur with any cellular system, e.g. confluent cell monolayer, suspension cells
or plated cells, wherein the substrate’s binding site to the transporter is a permeability
barrier away from where the substrate is added. The key component to this overestimate
is the small cytosolic volume of the cell systems compared with the extracellular volume,
e.g. the Transwell chambers. In this analysis, there are no other transporters in the model,
aside from P-gp. If there were additional transporters, which for some substrate/inhibitors
there may be, they would become part of the “passive permeability” coefficients.
160
Materials and Methods
Simulations. For these simulations, we have assumed simple competitive inhibition be-
tween the substrate and the inhibitor. Reality is more complex. P-gp has at least 2 eﬄux
pathways which are independent of one another at low concentrations of probe-substrate
and inhibitor-substrate like amprenavir and quinidine (Acharya et al., 2006). At high
concentrations of either substrate or inhibitor the binding sites of the eﬄux pathways are
competitive and cooperative. When inhibitor concentrations were near their IC50, binding
was simply competitive (Acharya et al., 2006).
We also treat the cells as static passive permeability barriers, so that passive perme-
ability coefficients are constant in time. Again, reality is more complex. For all drugs we
have tested, there is an initial increase in the passive permeability coefficients and a steady
state is achieved eventually (Tran et al., 2005; Acharya et al., 2006). For amprenavir and
quinidine, this increase is not due to any “loading” of the cells, as both drugs have es-
sentially perfect mass balance at all times. For our simulations here, these transients will
be ignored, since their inclusion would make the analysis more complex without affecting
any of our conclusions.
Obviously, we can only measure the overall apical chamber to basolateral chamber,
A>B, and overall basolateral chamber to apical chamber, B>A, passive permeability of the
drugs to give the measured value for the coefficients PBA and PAB. However, for fitting the
mass action kinetics, we need individual membrane passive permeability coefficients PAC ,
apical chamber to cytosol, and PBC , basolateral chamber to cytosol. Often, PBA 6= PAB
until a steady-state occurs, which can be several hours (Tran et al, 2005; Acharya et al.,
2006). As explained in Tran et al. (2005), the simplest mix of experiment and theory was
to set PAC= PAB and PBC =PBA to account for this asymmetry and to capture the basic
elements of the kinetic process.
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We used the stiffest integrator in MATLAB, ode23s, with absolute and relative toler-
ances set up to 10−10. Other MATLAB integrators, while faster, were not accurate enough
at the later times of simulations. Further details can be found in Tran et al. (2004, 2005)
and Acharya et al. (2006).
P-gp Activity. To fit the [IC50] by P-gp activity, we use the same equation as in
Rautio et el. (2006):
P − gp Activity =
∣∣∣∣nmol([I], total)− nmol([I] or [I] = 0, GF120918)nmol([I] = 0, total)− nmol([I] = 0, GF120918)
∣∣∣∣ (11.1)
where nmol([I],total) is the nmol substrate transported at some time t in the presence of
[I]=inhibitor concentration. nmol([I] or [I]=0,GF120918) is the nmol substrate transported
at some time t in the presence of the potent P-gp inhibitor GF120918 (Rautio et al., 2006),
which is the same whether or not the other inhibitor I is present. We will use the A>B
direction to analyze inhibition because it is more sensitive to the binding of substrate
to P-gp (Tran et al., 2005), although we have found in this work that analyzing B>A
transport gives essentially the same results. Since P-gp reduces total substrate transport
in the A>B direction, the equation as stated would give a negative number, so we simply
take the absolute value, as shown in the equation.
Thus, in either direction, the fraction of P-gp activity is 1 without inhibitor and
decreases as the inhibitor concentration increases. The inhibitor concentration at which
the P-gp activity is 0.5 is called the IC50. Without inhibitor, a certain fraction of P-gp
will be bound to substrate, depending upon the substrate concentration. At the IC50,
half of that fraction of P-gp will be bound by a competitive inhibitor. If the binding is
not competitive, different equations must be used.
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Kinetic Model of Transport across a Confluent Cell Monolayer
Figure 1 is a cartoon of a confluent cell monolayer, featuring the polarized MDCKII-
hMDR1 cells, where the basolateral membrane is attached to the polycarbonate filters
and P-gp (upward arrows) expressed on the apical surface. The apical and basolateral
chambers are kept separate by the tight junctions. Active transport by P-gp occurs uni-
directionally, with substrate binding to a site on P-gp within the apical membrane inner
monolayer and with eﬄux into the apical chamber (Loo and Clarke, 2005; Lugo and
Sharom, 2005). For many substrates, including those we use, passive permeability is a
significant fraction of total transport and is quantitatively analyzed separately using the
P-gp inhibitor, GF120918 (Tran et al., 2004, 2005; Acharya et al., 2006).
With the confluent cell monolayer system, we measure the concentration of substrate in
the apical chamber, denoted CA, and the basolateral chamber, denoted CB. However, the
concentration of substrate in the cytosol, denoted CC , and in the inner plasma membrane
in contact with the P-gp binding site, denoted CPC , cannot (yet) be measured rigorously in
real time. These internal concentrations are variables of the mass action model and fitted
by elementary rate constants for well-defined kinetic barriers, according to the measured
values of CB and CA over time (Tran et al., 2005; Acharya et al., 2006). We use the
simplest Michaelis-Menten mass action reaction to model P-gp:
T0 + Cpc
k1

kr
T1
k2−→ T0 + CA (11.2)
where T0 is the empty transporter, CPC the substrate in the apical membrane inner
monolayer, T1 is the transporter bound by substrate and CA the substrate after eﬄux into
the apical chamber. Although we have shown that P-gp has more than one eﬄux binding
site, at inhibitor concentrations near the IC50, P-gp behaved like a simple single compet-
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itive site transporter (Acharya et al., 2006). Likewise, while some of these substrates may
use other transporters within the MDCKII cell line, that is not part of these simulations,
but their effect would only be to change the “values” of passive permeability coefficients.
ATP hydrolysis is not part of this model, since it occurs intracellularly and cannot be
measured rigorously over time. However, we found that the cells do not lose any capacity
for drug transport over 6 hour incubations (Tran et al., 2005; Acharya et al., 2006),
implying that cellular ATP levels remain adequate for full P-gp function throughout the
6 hour long experiment.
Table 1 shows the median consensus values of the elementary parameters used to fit
the transport kinetics of amprenavir, quinidine and loperamide (Acharya et al., 2006).
Each parameter fitted had a range that gave good fits to all the data for over 6 hours of
transport. While the precision of these estimates varies, that precision is not important
for this work. We only use these median values for each of the three drugs to create a
range the values of the “virtual” substrates and inhibitors which are physiologically and
pharmaceutically relevant. If the values of the medians shown in Table 1 were increased or
decreased within their standard deviations, there would be no effect upon our conclusions.
We found that all three drugs had essentially the same rate constant for association to
P-gp, k1, and essentially the same estimated surface density for eﬄux active P-gp, T(0),
which was a benchmark for the validity of our mass action model and kinetic analysis
(Tran et al., 2005; Acharya et al., 2006). The values in the Table make considerable
sense for P-gp function and structure (Tran et al., 2005; Acharya et al., 2006). In our
simulations, these two parameters are held fixed at the values shown.
This leaves two other kinetically significant parameters characterizing substrate and
inhibitor interactions with the confluent cell monolayer and P-gp, both of which depend
upon the substrate:
1. k2, the eﬄux rate constant of the substrate and inhibitor from P-gp into the apical
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space.
2. kr, the dissociation rate constant of the substrate and inhibitor from P-gp back into
the inner apical membrane. The binding constant of the substrate and inhibitor to
P-gp from the inner monolayer of the apical membrane is defined by the ratio of the
fitted rate constants, i.e. KC = k1/kr.
The partition coefficient of the substrate and inhibitor between the inner monolayer of
the apical membrane and the cytosol of the cell is denoted KPC . The product of KPCKC
is the binding constant to P-gp relative to the cytosolic concentration of substrate, so
that the dissociation constant of the substrate to P-gp, relative to the cytosol, is KI,Aq =
1/(KPCKC). This will become quite important below when the question of rank order of
inhibitors is addressed.
The two other partition coefficients, KBO, between the basolateral chamber and the
outer basolateral membrane monolayer and, KAO, between the apical chamber and the
outer apical membrane monolayer, see Fig. (1), have also been estimated independently
(Tran et al., 2005). However, while their particular values can shift concentrations slightly,
this has no affect on the conclusions we reach.
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Results & Discussion
Figure 2 shows the simulation of the nmol transported over time for an “amprenavir-
like” probe substrate, starting with 1µM in the apical chamber, in the A>B direction
as a function of the concentration of the “quinidine-like” inhibitor, whose concentration
[I] in (µM) shown beside each curve. The respective parameters in Table 1 are used.
Complete inhibition of P-gp, e.g. by GF120918, is shown by the thick black line, which
represents just transcellular and/or paracellular passive permeability since there are no
other transporters in this model.
The IC50 in this simulation is clearly in the range of 1-2µM at all times, as indicated
by the vertical dotted lines shown at the 2, 4 & 6 hr time points. However, the “quinidine-
like” inhibitor has a KI,Aq=0.1µM, as can be calculated from Table 1 and shown in Table
2. Thus, the IC50 is 10-20 times larger than the KI,Aq used to calculate these simulations
in the first place. The simulations are without error and assume that transport is only
by P-gp and passive permeability. Clearly, the overestimate we observe experimentally
(Acharya et al., 2006) is due to the elementary rate constants, not experimental ambiguity.
In order to determine which parameters caused the overestimate, we followed the
strategy used in Bentz et al. (2005), which was to let the kinetic parameters for both
substrate and inhibitor range between and around those values we had fitted for am-
prenavir, loperamide and quinidine. This creates virtual substrates and inhibitors, with
pharmaceutically relevant parameters.
Figure 3 shows the P-gp activity as open squares calculated from Eq.(2), P-gp specific
nmol transported, using 2hr data from simulation in Fig. (2), replotted on a log-log plot
with 0.1-30µM of inhibitor. This is the same equation used in Rautio et al. (2006). The
closed squares show the fraction of P-gp bound by substrate, normalized to the amount
bound in the absence of inhibitor. Because we are doing simulations, we “know” this
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number, which is the theoretically correct measure of the IC50. While not identical,
both measures of relative inhibition are in excellent agreement. The difference is that
the nmol transported calculation of P-gp activity ignores backflow of substrate, which
slightly underestimates the total amount of substrate actually crossing into the basolateral
chamber (Tran et al., 2005). The KI,Aq =0.1µM for the inhibitor is shown by the large
X on the x-axis, showing the 14-fold overestimate of KI,Aq by the IC50. We call the ratio
of IC50/ KI,Aq the overestimate value, which is what we will explain in this work at the
molecular level.
We have found that the inhibitor’s parameters do not affect the overestimate value
of IC50/ KI,Aq (data not shown). For example, increasing the binding constant of the
inhibitor 10-fold did cause the KI,Aq to decrease 10-fold, as expected, but the IC50 also
decreased 10-fold. Thus the overestimate was unaffected. Accordingly, decreasing the
binding constant of the inhibitor 10-fold caused the commiserate 10-fold increase of KI,Aq
and the IC50. None of the inhibitor’s kinetic values had a significant effect on the over-
estimate, at least for the first two hours of transport. Changes in the inhibitor’s eﬄux
rate constant, k2, also did not change the overestimate, basically because the experimental
protocol used (Acharya et al., 2006; Rautio et al, 2006) held the inhibitor concentration
essentially constant in all compartments.
Thus the value of IC50/KI,Aq is due to only substrate parameters. Starting from the
mass action equations (Tran et al., 2005; Acharya et al., 2006), we have found that the
ratio of IC50/KI,Aq to be approximated by the equation:
[IC50]
KI,Aq
∼=
[
VAOT (0)
4A
] [
KPCKCk2
0.5 ∗ (PBC + PAC)
]
(11.3)
The first bracketed term contains general system parameters: the surface density of
P-gp in the apical membrane, i.e. the volume of the apical membrane of the entire con-
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fluent cell monolayer (roughly VAO ≈ 0.5nL, Tran et al., 2005) times the concentration of
eﬄux active P-gp in the apical membrane divided by 4 times the area of the Transwell
insert. Thus, the more P-gp there is, the greater the overestimate. The second bracketed
term contains the substrate specific kinetic parameters. The overestimate increases with
the substrate binding constant to P-gp from the membrane, KC , the substrate partition
coefficient into the cytosolic side of the plasma membrane, KPC , and the eﬄux rate con-
stant for the substrate, k2. The fitted values for these parameters are found in Table 1.
These terms are responsible for the eﬄux kinetics. So increased P-gp mediated eﬄux ki-
netics decreases the substrate cytosolic concentration and increases the overestimate. On
the other hand, increasing the substrate passive permeability coefficients, PAC and PBC ,
increases the substrate cytosolic concentration and decreases the overestimate. Obviously,
if the passive permeability coefficients become large enough, the membranes cease being
permeability barriers and the system becomes like an aqueous enzyme.
The deviation of Eq.(3) is straightforward, but quite lengthy and depends upon the
simulations for guidance in choosing which terms are significant and which terms are
negligible. In lieu of showing the derivation, we will demonstrate its accuracy. When we
create a virtual substrate using amprenavir’s parameters, from Table 1, except that both
PAC and PBC are variable, then Eq.(3) becomes
[IC50]
KI,Aq
∼= 6, 600nm/s
0.5 ∗ (PBC + PAC) (11.4)
To check this approximate equation against exact calculations, we allowed both PAC
and PBC to range between 20-2000 nm/s, which more than covers the known range
for these parameters, and looked at all possible combinations. Figure 4 shows the of
IC50/KI,Aq plotted against these passive permeability on a log-log plot. These values are
for the 2hr time point, but any time point from 2-6 hrs gives the same basic result. The
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line is Eq. (4), not a least-squares fit, which on a log-log plot has an x-intercept of about
6,600, as predicted. The better fits, shown by O’s are for cases where PBC/PAC < 10,
i.e. where both membranes, apical and basolateral, contribute to the overall passive per-
meability, which is likely to be the case for biological membranes, in the absence of other
transporters. The worse fits, denoted by X’s, are for cases where PBC/PAC ≥ 10, which
are cases where only apical membrane determines the transcellular passive permeability,
which can also be considered as a mimic for the case where there is a basolateral trans-
porter.
The arrow in Fig(3) points to 0.5 ∗ (PAC + PBC) ∼ 6600 nm/s, which is where the
simple approximation of Eq. (5) for IC50/KI,Aq extrapolates to about 1, i.e. where the
membrane is as permeable as water. In reality, Eq.(3) would not extrapolate accurately,
since it becomes less accurate as the passive permeability increases, which accounts for
the greater scatter as (PAC + PBC) increases.
To further test the accuracy of Eq.(3), we have made further simulations where the
values of k2, KC , T(0) or VAO are increased or decreased by 10-fold from the amprenavir
values used in Eq.(4). In all cases, the value of IC50/KI,Aq increased or decreased by
10-fold, more or less, showing that Eq.(3) is a reasonable approximation for a broad range
of parameters centered around amprenavir and quinidine as probe substrates.
Table 2 shows the IC50 values we extracted from the data in Acharya et al. (2006)
for several pairs of P-gp substrates and the fitted values for KI,Aq, from the elementary
rate constants, calculated from the values shown in Table 1. The experimental ratios of
IC50/KI,Aq range from about 20-60. When corrected by Eq. (3), using the parameters
in Table 1, the overestimates are reduced to 1.5-4. Thus, the correction by Eq.(3) works
well in practice.
What remains is to understand the physical reason for the overestimate, since it sug-
gests a fundamental kinetic property of the confluent monolayer. The simulations show
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for A>B transport that the cytosolic concentration of substrate reaches a “quasi”-steady-
state within a few minutes, even with substrate passive permeability coefficients as small
as 20nm/s, like digoxin (Rautio et al., 2006). This is not the final steady-state achieved
eventually, e.g. after several hours, as shown in Fig. 2, when P-gp eﬄux plus the small
amount of B>A passive permeability, is equal to the A>B passive permeability. The
initial “quasi”-steady-state in the cytosolic substrate concentration persists as the baso-
lateral substrate concentration slowly increases and apical substrate concentration slowly
decreases compartment. Eventually, the “quasi”-steady state breaks as the basolateral
concentration of substrate approaches that of the cytosolic concentration.
How can this initial “quasi”-steady-state be established in seconds to minutes, when
the final steady-state requires hours? The answer lies in the small volume of cytosol com-
partment of the confluent cell monolayer. In Tran et al. (2004), we showed that the passive
permeability between a donor compartment of volume VD and a receiver compartment of
volume VR, through a single-barrier membrane of area A and a passive permeability coef-
ficient P, gives a receiver side concentration of:
CR(t) =
CD(0)VD
VD + VR
(
1− exp
{
−(VD + VR)
VDVR
PAt
})
(11.5)
where CD(0) is the initial donor side concentration. This equation also assumes that
the substrate has no mass balance problems and that there is initially no substrate in
the receiver compartment. If this is not the case, then a more complicated equation can
be used (Tran et al., 2004), but the same conclusions would be reached. This equation
applies only to pure passive permeability, so it eventually reaches true equilibrium.
A convenient measure of the time required to reach a “steady-state” value is the
halftime value, where the exponential term=0.5. Then:
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t0.5(D > R) =
1.44VDVR
(VD + VR)PA
(11.6)
For A>B transport, the Transwell system has VD = 0.5mL, VR = 1.5mL and A=1.13
cm2 (Acharya et al., 2006) When the passive permeability coefficient is P=450 nm/sec,
e.g. like amprenavir in Table 1, then t0.5(A > B) ∼ 3 hours. On the other hand, for the
A>C transport to the cytosol, with VR = 1µL (Tran et al, 2005), t0.5(A > C) ∼ 20 sec.
Thus, the initial “quasi”-steady-state between the apical chamber and the cytosol can be
established within seconds, because the receiver volume is so small.
Now, the simulations show that the greater the eﬄux rate out of the cytosol relative to
the passive permeability into the cytosol, i.e. as the right hand side of Eq. (3) increases,
the cytosolic concentration of substrate decreases and the smaller the fraction of P-gp
bound by substrate (data not shown). This is the actual mechanism of the overestimate
value.
Figure 5 shows the concentration of substrate-bound P-gp as a function of inhibitor
concentration. The solid line simulation uses the same parameters as Fig.(2), showing that
without inhibitor that about 1µM of P-gp is bound by substrate. To reduce the substrate-
bound P-gp by 50% from the inhibitor-free value required IC50=1.2µM inhibitor. The
dotted line simulation has the PAC reduced from 400 nm/s to 200nm/s, which reduces
the inhibitor-free concentration of substrate-bound P-gp to about 0.5µM. Because a one-
site binding curve flattens out as the fraction bound goes to zero, even the Henderson-
Hasselbach pH curve, the reduction of substrate-bound P-gp is more shallow per µM
inhibitor added than in the first case. More inhibitor is required to reduce the substrate-
bound P-gp by 50%, i.e. IC50=2.2µM. In both cases, KI,Aq=0.1µM is the same. The
overestimate is 12-fold and 22-fold, respectively.
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Conclusions
Based upon the fitted elementary kinetic parameters that define the P-gp mediated trans-
port in a confluent monolayer of MDCKII-hMDR1cells (Tran et al., 2005; Acharya et al.,
2006), we have investigated the usage of an IC50 experiment to characterize the inhibi-
tion of transport and the inhibitor dissociation constant. The simulations show that the
IC50 will over-estimate the dissociation constant of the inhibitor to P-gp relative to the
cytosol, KI,Aq, by a factor which depends upon probe substrate kinetic parameters and
cell parameters. This factor is approximated by Eq.(3), whose accuracy is shown in Fig.
(4). No part of the derivation for Eq.(3) required that substrate actually pass into the
receiver chamber, so that all of the conclusions we reach here hold for any small volume
system, e.g. suspension or plated cells.
The basic reason for this overestimate is the small volume of the cytosolic space, as
compared with the apical and basolateral chambers, which in the A>B direction causes
an initial “quasi”-steady-state in cytosolic concentration to be established in seconds to
minutes, even with poorly permeable substrates. This “quasi”-steady-state is established
by the balance of P-gp mediated cytosol?apical chamber eﬄux and the passive permeation
apical chamber→ cytosol. The steady-state is “quasi” because there is a net donor cham-
ber → receiver chamber flux, which eventually evolves to the final steady-state, where all
concentrations are stationary and the cytosolic substrate concentration equals that of the
basolateral chamber. In the B>A direction, the derivation of Eq.(3) is more complicated,
but the final equation is the same and the calculations give the same answers. Here we
have considered only the simpler A>B case.
In the absence of inhibitor, the greater the amplitude of eﬄux parameters in Eq.(3), the
right hand side of the equation, the smaller the cytosolic concentration at this steady-state
and, thus, the smaller the concentration of substrate-bound P-gp. Addition of inhibitor
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will reduce the concentration of substrate-bound P-gp, but the smaller the “inhibitor-free”
substrate-bound P-gp, the larger the amount of inhibitor required to reach the IC50. This
is simply the nature of a 1-site binding reaction: more P-gp mediated eﬄux pushes the
system further out onto the tail-end of the binding curve. To use this correction factor to
estimate the inhibitor dissociation constant, KI,Aq, requires knowing the elementary rate
constants of the substrate, as shown in Table 1.
The primary function of IC50 in drug studies is to rank order inhibitors with respect
to a particular probe-substrate (Rautio et al., 2006). The rank order of P-gp inhibitors
using a single probe substrate with the same in vitro cell line would not be affected by
the correction factor given by Eq.(3), since it would be the same correction for all IC50
values. Changing the probe-substrate with the same in vitro cell line would change the
IC50 values, but would not affect the rank order, since the new correction factor would
apply to all inhibitor IC50 values.
The stability of the inhibitor rank order in another in vitro cell line or in vivo is less
clear. The correction factor, i.e. the right-hand side of Eq.(3), would not change the
rank order. However, in a different cell line or in vivo, the relative partition coefficients
of the inhibitors to the cytosolic side of the plasma membrane are part of KI,Aq. For
example, suppose that two drugs had equal binding constants for P-gp from the membrane,
then their dissociation constants relative to the cytosol would depend entirely upon the
relative partition coefficient to the inner plasma membrane. Whichever drug had the larger
partition coefficient would have the smaller IC50. Tran et al. (2005) found quite a lot of
sensitivity of partition coefficients between the three drugs we used and the three different
lipid compositions, which are crude mimics of biological membranes. In a different cell
line or in vivo, it is very hard to predict whether the partition coefficients would remain in
the same rank order. Independent measurements of the partition coefficients would clarify
the extrapolation problem.
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Our final point is that equations developed for use with soluble enzymes with
soluble drugs cannot be expected to give accurate results for membrane transporters
with substrates which must cross a permeability barrier into a much smaller volume
to reach the transporter binding site. Our analysis has proven that both the KM
(Bentz et al., 2005) and the IC50 fittings for the confluent cell monolayer do not
yield coefficients which mean what they do for soluble enzymes. Only the elementary
kinetic parameters derived from the comprehensive mass action kinetic analysis can
yield a reliable starting point for extrapolations.
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Figure Legends
Figure 1. Model of a confluent cell monolayer, with the apical membrane on top and the
basolateral membrane on the bottom, where it binds to the polycarbonate insert. Passive
permeability occurs in both directions. P-gp expressed on the apical membrane transports
substrate from the inner apical membrane monolayer into the apical chamber. The con-
centration of substrate in the apical and basolateral chambers, CA and CB, are measured,
while the concentration of substrate in the inner plasma membrane, CPC , and the cytosol,
CC , are predicted as part of the mass action modeling and data fitting process described
in Tran et al. (2005) and Acharya et al. (2006).
Figure 2. Simulation of nmol transported over time for 0.1µM of an “amprenavir-like”
substrate, i.e. using the amprenavir kinetic parameters shown in Table 1, in the presence
of increasing concentrations of an inhibitor with the same kinetic parameters as quinidine,
which makes KI,Aq=0.1µM. Complete inhibition of P-gp by GF120918 is simulated by the
thick black line on the top. “Quinidine-like” inhibitor concentrations are shown beside
the thin black lines. We use the A>B inhibition because this data is more sensitive to
binding to P-gp (Tran et al., 2005), although using B>A simulations give basically the
same results. Clearly, the IC50 is in the range of 1-2 µM, i.e. 10-20 times larger than the
KI,Aq.
Figure 3. The fraction of P-gp mediated transport (open boxes) in the A>B direc-
tion substrate at 2 hours from Fig. 2, as a function of inhibitor concentration, on a log
plot from 0.1-100µM, with 0.1µM substrate, from Eq.(2). This curve allows us to estimate
the IC50 accurately. The closed boxes show the fraction of substrate-bound P-gp, showing
that the P-gp activity estimated from nmol transported is quite accurate.
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Figure 4. A log-log plot of the calculated values of IC50/ KD,Aq at 2 hours, calcu-
lated as shown in Fig. 4 for the amprenavir-like substrate with variable passive perme-
ability coefficients, plotted against the average substrate passive permeability into the
cytosol, 0.5*(PAC+PBC)(nm/s). The passive permeability coefficients, PAC and PBC ,
each vary from 20-2000 nm/sec and all combinations are calculated. The linear corre-
lation with Eq.(3) is quite good, with a correlation coefficient of R2 = 0.9 for all the
points and R2 = 0.98 for the circles, which are for cases where PBC/PAC < 10, i.e. where
both membrane contribute to the transcellular passive permeability. The arrow points to
0.5*(PAC+PBC)∼ 6600 nm/s, which is where Eq.(4) for IC50/KI,Aq extrapolates to 1 and
where the membrane would be as permeable as water.
Figure 5. The concentration of substrate-bound P-gp (fig 5A) or the fraction of P-
gp bound by substrate (fig 5B) is shown as a function of inhibitor concentration for
A>B transport. The solid line shows the case for the amprenavir-like substrate, with
the parameters from Table 1, PBC=500 nm/sec and PAC=400 nm/sec, inhibited by the
quinidine-like compound, i.e. the same as in Figs. 2-4. To reduce the inhibitor free value
of substrate-bound P-gp from about 1µM to 0.5 µM required 1.2 µM of inhibitor. On
the other hand, if the amprenavir-like substrate’s PAC is reduced to 200 nm/s, then the
inhibitor free value of substrate-bound P-gp is reduced to about 0.5µM, which requires
about 2.2 µM of inhibitor to reduce the substrate-bound P-gp concentration by 50%, i.e.
nearly twice as much. Given that the “quasi”-steady-state which reduces the cytosolic
substrate concentration and, hence, the concentration of substrate-bound P-gp, this is the
root cause of the overestimate of the KI,Aq by the IC50.
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Figure 11.1: Paper 3: Figure 1 - Model of a confluent cell monolayer.
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Figure 11.2: Paper 3: Figure 2 - Simulations show IC50 for an amprenavir-like substrate
transport inhibited by quinidine-like inhibitor is 1 - 2µM.
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Figure 11.3: Paper 3: Figure 3 - The fraction of substrate bound P-gp as a function of
inhibitor concentration.
Figure 11.4: Paper 3: Figure 4 - Overestimation of KI,Aq by the IC50 as a function of
average passive permeability into the cytosol.
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Figure 11.5: Paper 3: Figure 5a - The concentration of substrate-bound P-gp as a function
of inhibitor concentration.
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Figure 11.6: Paper 3: Figure 5b - Fraction of substrate-bound P-gp as a function of
inhibitor concentration.
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Table 1
Figure 11.7: Paper 3: Table 1 - Fitted Parameter Valuesa
185
Legend for Table 1.
a These are median values obtained for the association rate constant fitted in Tran et
al. (2005) and in Acharya et al. (2006). This is the rate constant from flip-flop across the
basolateral membrane to association with the P-gp binding site. The route appears to be
lipid lateral diffusion controlled through the inner plasma monolayer.
b Median values for the density of eﬄux active P-gp in the apical membrane inner mono-
layer for each of the three drugs. As discussed in Tran et al. (2005) and Acharya et al.,
(2006), this number may be roughly 10 times smaller than the true surface density since
only substrate released at the tips of the microvilli are likely to reach the apical chamber,
rather than being absorbed back into the microvilli membrane and starting over.
c Median values for the product of k2T(0), or the “Vmax”, of P-gp.
d Median value for the eﬄux rate constant k2.
e In reality, three partition coefficients are needed to simulate model data: KPC is between
the cytosol and the inner plasma monolayer; KBO is between the basolateral chamber and
the outer basolateral monolayer; and KAO is between the apical chamber and the outer
apical monolayer. Partition coefficients were estimated using 0.1µm extruded unilamellar
liposomes (LUV) whose lipid compositions mimic, in a very crude way, the lipid composi-
tions of the respective membrane monolayers. As explained in Tran et al. (2005), direct
measurements using cells would be difficult since the drugs used are so permeable that
only overall cell average partition coefficients could be obtained.
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f Median value for the substrate binding constant from inner apical membrane mono-
layer to P-gp.
g This is the steady-state value for the drug’s passive permeability coefficient. In re-
ality, the passive permeability coefficients took from 15 min to 4 hrs to reach steady-state
and PaBA was not the same as PaAB until their steady-state was reached (Tran et al.,
2004, 2005; Acharya et al., 2006). Using these transient conditions would make the cal-
culations and explanations much more complex, without changing any conclusions. We
assumed the ideal situation of a static symmetric passive permeability barrier using the
values achieved at the final steady-state.
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Table 2
Figure 11.8: Paper 3: Table 2 - IC50 values and Corrections to estimate KI,Aq
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Legend for Table 2.
The IC50, passive permeability coefficients PaAB, and fitted values for the aqueous in-
hibitor dissociation constant KI,Aq were published in Acharya et al. (2006).
a IC50 fitted in Acharya et al. (2006).
b The dissociation constant for the substrate relative to the cytosol is KI,Aq = 1/(KPC ∗
KC), using the parameters in Table 1.
cThe “average” passive permeability coefficients from the chambers into the cytosol, using
the values from Table 1.
dThe “corrected” KI,Aq using the measured IC50 and Eq.(3).
